[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1251
1. Tsutsumi Y, Kanamori H, Yamato H, Ehira N, Kawamura T, Obara S, Tanaka J, Asaka M, Imamura M, Masauzi N: Lung infiltration of adult T-cell leukemia cells following the administration of arsenic trioxide. Lung infiltration of ATL by AS(2)O(3). Med Hypotheses; 2006;66(1):201-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung infiltration of adult T-cell leukemia cells following the administration of arsenic trioxide. Lung infiltration of ATL by AS(2)O(3).
  • [MeSH-major] Arsenicals / adverse effects. Arsenicals / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemic Infiltration / chemically induced. Lung / pathology. Oxides / adverse effects. Oxides / therapeutic use

  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16165312.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Deltaretrovirus Antibodies; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


2. Sudhakar N, Nirmala K, Rajalekshmy KR, Rajkumar T: Does TAL-1 deletion contribute to the high incidence of T-cell acute lymphoblastic leukemia in South Indian patients? Asian Pac J Cancer Prev; 2008 Jan-Mar;9(1):127-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does TAL-1 deletion contribute to the high incidence of T-cell acute lymphoblastic leukemia in South Indian patients?
  • BACKGROUND: The incidence of T-cell acute lymphoblastic leukemia (T-ALL) in South India is very high (43.1%) when compared to the Western countries (10-20%).
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Incidence. India / epidemiology. Male. Polymerase Chain Reaction. Sequence Deletion. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18439091.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Proto-Oncogene Proteins; 135471-20-4 / TAL1 protein, human
  •  go-up   go-down


3. Li T, Xue Y, Zhang J, Chen S, Pan J, Wu Y, Wang Y, Shen J: Isodicentric 20q- in two cases of B-cell acute lymphocytic leukemia with the respective t(9;20)(p11;q11.2) and t(9;22)(q34;q11.2). Cancer Genet Cytogenet; 2008 Feb;181(1):55-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isodicentric 20q- in two cases of B-cell acute lymphocytic leukemia with the respective t(9;20)(p11;q11.2) and t(9;22)(q34;q11.2).
  • The cytogenetic anomaly der(20)del(20)(q11.2q13.3)idic(20)(p11), or idic(20q-) in short form, has been reported in 13 cases of myelodysplastic syndrome, one case of chronic myelomonocytic leukemia, and one case of acute myeloid leukemia since 2004.
  • Here we report the cases of two patients with B-cell acute lymphocytic leukemia (ALL) having a novel idic(20q-).
  • One was a 34-year-old man with B-cell ALL whose leukemic cells at presentation had a karyotype of 45,XY,dic(9;20)(p11;q11.2); at relapse, a small marker chromosome was found coexisting with the dic(9;20).
  • The other was a 39-year-old woman with Ph-positive B-cell-ALL whose leukemic cells contained both t(9;22)(q34;q11.2) and a small marker chromosome.
  • [MeSH-major] Chromosomes, Human, Pair 20. Chromosomes, Human, Pair 22. Chromosomes, Human, Pair 9. Leukemia, B-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Chromosome Banding. Chromosome Mapping. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18262055.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Rajasingh J, Raikwar HP, Muthian G, Johnson C, Bright JJ: Curcumin induces growth-arrest and apoptosis in association with the inhibition of constitutively active JAK-STAT pathway in T cell leukemia. Biochem Biophys Res Commun; 2006 Feb 10;340(2):359-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curcumin induces growth-arrest and apoptosis in association with the inhibition of constitutively active JAK-STAT pathway in T cell leukemia.
  • Adult T cell leukemia is an aggressive and frequently fatal malignancy that expressess constitutively activated growth-signaling pathways in association with deregulated growth and resistance to apoptosis.
  • But the effect and mechanism of action of curcumin on T cell leukemia is not known.
  • To investigate the antitumor activity of curcumin in T cell leukemia, we examined its effect on constitutive phosphorylation of JAK and STAT proteins, proliferation, and apoptosis in HTLV-I-transformed T cell lines.
  • HTLV-I-transformed T cell leukemia lines, MT-2, HuT-102, and SLB-1, express constitutively phosphorylated JAK3, TYK2, STAT3, and STAT5 signaling proteins.
  • In vitro treatment with curcumin induced a dose-dependent decrease in JAK and STAT phosphorylation resulting in the induction of growth-arrest and apoptosis in T cell leukemia.
  • The induction of growth-arrest and apoptosis in association with the blockade of constitutively active JAK-STAT pathway suggests this be a mechanism by which curcumin induces antitumor activity in T cell leukemia.
  • [MeSH-major] Apoptosis / drug effects. Curcumin / pharmacology. Growth Inhibitors / pharmacology. JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors. Leukemia, T-Cell / enzymology. Leukemia, T-Cell / pathology. MAP Kinase Signaling System / drug effects. Protein Kinase Inhibitors / pharmacology
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / pharmacology. Cell Line, Transformed. Cell Line, Tumor. Humans. Janus Kinase 3. Phosphorylation / drug effects. Protein-Tyrosine Kinases / antagonists & inhibitors. Protein-Tyrosine Kinases / biosynthesis. Protein-Tyrosine Kinases / genetics. STAT3 Transcription Factor / antagonists & inhibitors. STAT3 Transcription Factor / biosynthesis. STAT3 Transcription Factor / genetics. STAT5 Transcription Factor / antagonists & inhibitors. STAT5 Transcription Factor / biosynthesis. STAT5 Transcription Factor / genetics. TYK2 Kinase

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CURCUMIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16364242.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 R21CA106207-01; United States / NINDS NIH HHS / NS / R01 NS42257-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Growth Inhibitors; 0 / JAK3 protein, human; 0 / Protein Kinase Inhibitors; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / STAT5 Transcription Factor; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Janus Kinase 3; EC 2.7.10.2 / TYK2 Kinase; EC 2.7.10.2 / TYK2 protein, human; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; IT942ZTH98 / Curcumin
  •  go-up   go-down


5. Kuchinskaya E, Heyman M, Grandér D, Linderholm M, Söderhäll S, Zaritskey A, Nordgren A, Porwit-Macdonald A, Zueva E, Pawitan Y, Corcoran M, Nordenskjöld M, Blennow E: Children and adults with acute lymphoblastic leukaemia have similar gene expression profiles. Eur J Haematol; 2005 Jun;74(6):466-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Children and adults with acute lymphoblastic leukaemia have similar gene expression profiles.
  • OBJECTIVES: To compare the gene expression pattern in children and adults with acute lymphoblastic leukaemia (ALL) in order to improve our understanding of the difference in disease biology and prognosis.
  • RESULTS: Unsupervised hierarchical cluster analysis revealed that, in spite of differences in outcome, patients clustered irrespective of age, first by T-cell or B-precursor immunophenotype, and second by cytogenetic changes within the B-precursor group.
  • No significant difference in gene expression was observed between samples with and without CDKN2A deletion within the B-precursor group.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Oligonucleotide Array Sequence Analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Child. Child, Preschool. Female. Fusion Proteins, bcr-abl / biosynthesis. Fusion Proteins, bcr-abl / genetics. Gene Deletion. Gene Expression Profiling. Genes, p16. Humans. Male. Philadelphia Chromosome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15876250.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


6. Yamamoto B, Li M, Kesic M, Younis I, Lairmore MD, Green PL: Human T-cell leukemia virus type 2 post-transcriptional control protein p28 is required for viral infectivity and persistence in vivo. Retrovirology; 2008 May 12;5:38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human T-cell leukemia virus type 2 post-transcriptional control protein p28 is required for viral infectivity and persistence in vivo.
  • BACKGROUND: Human T-cell leukemia virus (HTLV) type 1 and type 2 are related but distinct pathogenic complex retroviruses.
  • HTLV-1 is associated with adult T-cell leukemia and a variety of immune-mediated disorders including the chronic neurological disease termed HTLV-1-associated myelopathy/tropical spastic paraparesis.
  • In contrast, HTLV-2 displays distinct biological differences and is much less pathogenic, with only a few reported cases of leukemia and neurological disease associated with infection.
  • CONCLUSION: We provide direct evidence that p28 is dispensable for viral replication and cellular immortalization of primary T-lymphocytes in cell culture.

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 2.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2000 Mar;74(6):2655-62 [10684280.001]
  • [Cites] N Engl J Med. 2000 Mar 30;342(13):930-6 [10738051.001]
  • [Cites] J Biol Chem. 2000 Apr 21;275(16):11852-7 [10766811.001]
  • [Cites] J Virol. 2000 Dec;74(23):11270-7 [11070026.001]
  • [Cites] J Virol. 2001 Sep;75(18):8440-8 [11507189.001]
  • [Cites] J Virol. 2001 Oct;75(20):9885-95 [11559821.001]
  • [Cites] Nat Med. 2004 Feb;10(2):197-201 [14730358.001]
  • [Cites] J Virol. 2004 Apr;78(8):3837-45 [15047799.001]
  • [Cites] J Virol. 2004 Oct;78(20):11077-83 [15452228.001]
  • [Cites] Nature. 1983 Oct 6-12;305(5934):502-5 [6312323.001]
  • [Cites] Science. 1985 Aug 16;229(4714):675-9 [2992082.001]
  • [Cites] Nature. 1985 Dec 12-18;318(6046):571-4 [2999613.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jun;84(11):3653-7 [3035544.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Aug;84(15):5389-93 [3037548.001]
  • [Cites] Blood. 1988 Feb;71(2):363-9 [2827811.001]
  • [Cites] Nature. 1988 Jun 23;333(6175):776-8 [2838755.001]
  • [Cites] J Virol. 1990 Oct;64(10):4914-21 [2398533.001]
  • [Cites] Neurology. 1991 Jan;41(1):85-7 [1985300.001]
  • [Cites] J Virol. 1991 Aug;65(8):4408-13 [2072457.001]
  • [Cites] Lancet. 1992 Mar 14;339(8794):645-6 [1347339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8813-7 [1528897.001]
  • [Cites] Ann Neurol. 1993 Apr;33(4):411-4 [8489213.001]
  • [Cites] J Virol. 1995 Jan;69(1):387-94 [7983733.001]
  • [Cites] Virology. 1995 Jun 1;209(2):445-56 [7539968.001]
  • [Cites] J Virol. 1995 Oct;69(10):6297-303 [7666530.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1030-5 [8562927.001]
  • [Cites] J Virol. 1997 Feb;71(2):1181-90 [8995640.001]
  • [Cites] Virology. 1997 Oct 13;237(1):123-8 [9344914.001]
  • [Cites] J Virol. 1998 Jan;72(1):633-40 [9420268.001]
  • [Cites] J Virol. 1998 May;72(5):4458-62 [9557741.001]
  • [Cites] J Virol. 1998 Nov;72(11):8852-60 [9765430.001]
  • [Cites] J Virol. 1999 Jun;73(6):4856-65 [10233947.001]
  • [Cites] J Virol. 1999 Oct;73(10):8112-9 [10482560.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:620-42 [15569604.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 31;102(22):7994-9 [15911757.001]
  • [Cites] Mol Cell Biol. 2005 Jul;25(14):6178-98 [15988028.001]
  • [Cites] Retrovirology. 2005;2:16 [15743528.001]
  • [Cites] Retrovirology. 2005;2:30 [15882466.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5926-30 [16155599.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5931-7 [16155600.001]
  • [Cites] J Virol. 2005 Dec;79(23):14536-45 [16282453.001]
  • [Cites] J Virol. 2006 Jan;80(1):181-91 [16352542.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1980-8 [16263794.001]
  • [Cites] Blood. 2006 May 15;107(10):3976-82 [16424388.001]
  • [Cites] Virology. 2006 Oct 25;354(2):225-39 [16890266.001]
  • [Cites] J Virol Methods. 2007 Jun;142(1-2):159-68 [17337070.001]
  • [Cites] J Biol Chem. 2007 May 11;282(19):14608-15 [17360706.001]
  • [Cites] J Virol. 2000 Feb;74(3):1094-100 [10627519.001]
  • (PMID = 18474092.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA100730-06; United States / NCI NIH HHS / CA / P01 CA100730; United States / NCI NIH HHS / CA / CA100730; United States / NCI NIH HHS / CA / P01 CA100730-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Gene Products, tax; 0 / Retroviridae Proteins; 0 / Viral Proteins; 0 / tax protein, Human T-lymphotrophic virus 2
  • [Other-IDs] NLM/ PMC2405800
  •  go-up   go-down


7. Murata K, Yamada Y: The state of the art in the pathogenesis of ATL and new potential targets associated with HTLV-1 and ATL. Int Rev Immunol; 2007 Sep-Dec;26(5-6):249-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Almost 30 years have passed since adult T-cell leukemia (ATL) was identified as a new disease entity in Japan.
  • During this period, its causative agent, human T-cell leukemia virus (HTLV-1), was discovered, and a crucial role of the viral product Tax in ATL leukemogenesis was demonstrated.
  • Recently, another HTLV-1 product, HBZ, which is encoded on the negative strand, was found, and it has now become a subject of intensive research because of its possible activity in cell proliferation.
  • [MeSH-major] Human T-lymphotropic virus 1. Leukemia-Lymphoma, Adult T-Cell

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18027200.001).
  • [ISSN] 0883-0185
  • [Journal-full-title] International reviews of immunology
  • [ISO-abbreviation] Int. Rev. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic-Leucine Zipper Transcription Factors; 0 / CCR4 protein, human; 0 / Gene Products, tax; 0 / HBZ protein, human T-cell leukemia virus type I; 0 / NF-kappa B; 0 / Receptors, CCR4; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Viral Proteins
  • [Number-of-references] 90
  •  go-up   go-down


8. Karube K, Suzumiya J, Okamoto M, Takeshita M, Maeda K, Sakaguchi M, Inada T, Tsushima H, Kikuchi M, Ohshima K: Adult T-cell lymphoma/leukemia with angioimmunoblastic T-cell lymphomalike features: Report of 11 cases. Am J Surg Pathol; 2007 Feb;31(2):216-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell lymphoma/leukemia with angioimmunoblastic T-cell lymphomalike features: Report of 11 cases.
  • In adult T-cell lymphoma/leukemia (ATLL), the neoplastic lymphoid cells are usually medium-sized to large, often with pronounced nuclear pleomorphism compatible with the diagnosis of diffuse pleomorphic peripheral T-cell lymphoma.
  • We describe here 11 patients with the rare morphologic variant of ATLL, angioimmunoblastic T-cell lymphoma (AILT)-like type.
  • All patients were positive for antiadult T-cell leukemia/lymphoma-associated antigen, which is a specific antibody for human T-cell lymphotropic virus type-I.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. DNA, Viral / analysis. Female. HTLV-I Infections / virology. Humans. Male. Middle Aged. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255766.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / DNA, Viral
  •  go-up   go-down


9. Bellon M, Baydoun HH, Yao Y, Nicot C: HTLV-I Tax-dependent and -independent events associated with immortalization of human primary T lymphocytes. Blood; 2010 Mar 25;115(12):2441-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-cell leukemia virus type I (HTLV-I)-associated malignancies are seen in a small percentage of infected persons.
  • Tax expression was required for the growth of primary T cells, but was not sufficient to propel T cells into cell cycle in the absence of exogenous interleukin-2 (IL-2).
  • We also found disruption of putative tumor suppressors IL-16 and translocated promoter region (TPR) in Tax-immortalized and HTLV-I-transformed cell lines.
  • These data provide a better understanding of Tax functions in human T cells, and highlight the limitations of Tax, suggesting that other viral proteins are key to T-cell transformation and development of adult T-cell leukemia.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1998 Feb;72(2):1165-70 [9445014.001]
  • [Cites] J Clin Oncol. 2009 Jan 20;27(3):453-9 [19064971.001]
  • [Cites] Exp Cell Res. 1999 Mar 15;247(2):525-33 [10066380.001]
  • [Cites] J Virol. 1999 May;73(5):3709-17 [10196263.001]
  • [Cites] Oncogene. 1999 Apr 15;18(15):2441-50 [10229195.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5986-95 [16155605.001]
  • [Cites] EMBO J. 2006 Apr 19;25(8):1741-52 [16601696.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1021-9 [16569765.001]
  • [Cites] Int J Cancer. 2006 Nov 1;119(9):2090-7 [16786598.001]
  • [Cites] Oncogene. 2008 Feb 14;27(8):1135-41 [17704807.001]
  • [Cites] Apoptosis. 2008 Jun;13(6):733-47 [18421579.001]
  • [Cites] J Virol. 2008 Sep;82(17):8442-55 [18596104.001]
  • [Cites] Oncogene. 2000 Feb 10;19(6):827-30 [10698501.001]
  • [Cites] Blood. 2000 Jul 1;96(1):275-81 [10891462.001]
  • [Cites] Mol Cell Biol. 2000 Nov;20(22):8580-9 [11046153.001]
  • [Cites] J Biol Chem. 2000 Nov 17;275(46):35926-31 [10931836.001]
  • [Cites] J Immunol. 2001 Apr 15;166(8):4826-30 [11290757.001]
  • [Cites] J Virol. 2002 Apr;76(8):4022-33 [11907241.001]
  • [Cites] J Biomed Sci. 2002 Jul-Aug;9(4):292-8 [12145525.001]
  • [Cites] N Engl J Med. 2002 Nov 14;347(20):1593-603 [12432047.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(15):5269-81 [12861013.001]
  • [Cites] Blood. 2003 Aug 1;102(3):849-57 [12689947.001]
  • [Cites] Nat Med. 2004 Feb;10(2):197-201 [14730358.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3561-71 [15077181.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2523-31 [15226182.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 May;86(9):3351-5 [2541443.001]
  • [Cites] Mol Cell Biol. 1990 Jan;10(1):413-7 [2403646.001]
  • [Cites] Science. 1995 Jul 7;269(5220):79-81 [7604283.001]
  • [Cites] Oncogene. 1996 Apr 18;12(8):1645-52 [8622884.001]
  • [Cites] EMBO J. 1996 Apr 1;15(7):1607-14 [8612584.001]
  • [Cites] J Virol. 1997 Mar;71(3):1975-83 [9032329.001]
  • [Cites] FEBS Lett. 1997 Apr 14;406(3):263-6 [9136898.001]
  • [Cites] J Virol. 1997 Jun;71(6):4445-51 [9151835.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13897-902 [9391124.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2946-55 [18511807.001]
  • [Cites] Genes Dev. 2008 Nov 1;22(21):2926-31 [18981471.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3845-50 [9520455.001]
  • (PMID = 20093405.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016475; United States / NCI NIH HHS / CA / R01 CA115398; United States / NCI NIH HHS / CA / CA106258; United States / NCI NIH HHS / CA / CA115398; United States / NCI NIH HHS / CA / R01 CA106258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / Interleukin-2; 0 / tax protein, Human T-lymphotrophic virus 1
  • [Other-IDs] NLM/ PMC2845900
  •  go-up   go-down


10. Kennedy-Nasser AA, Bollard CM, Myers GD, Leung KS, Gottschalk S, Zhang Y, Liu H, Heslop HE, Brenner MK, Krance RA: Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant; 2008 Nov;14(11):1245-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen.
  • HLA-matched sibling donor (MSD) stem cell transplantation can cure>60% of pediatric patients with acute lymphoblastic leukemia (ALL), but <30% of patients will have a sibling donor.
  • The addition of alemtuzumab (Campath 1-H) to AD transplants produces in vivo T cell depletion, which may reduce the risk for GVHD.
  • We now report the outcome for 83 children with ALL (41 MSD, 42 AD) undergoing stem cell transplantation in first or second complete remission.
  • For children undergoing stem cell transplantation (SCT) from alternative donors, alemtuzumab with a myeloablative conditioning regimen resulted in DFS comparable to MSD.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antibodies, Neoplasm / administration & dosage. Antineoplastic Agents / administration & dosage. Donor Selection. Hematopoietic Stem Cell Transplantation. Living Donors. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Siblings. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal, Humanized. Child. Child, Preschool. Disease-Free Survival. Female. Graft Survival. Graft vs Host Disease / mortality. Humans. Infant. Male. National Health Programs. Philadelphia Chromosome. Recurrence. Remission Induction. Retrospective Studies. Risk Factors. Survival Rate. Transplantation, Homologous. United States

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18940679.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


11. Kuliszkiewicz-Janus M, Tuz MA, Kiełbiński M, Baczyński S, Jaźwiec B, Sladowska H: Platelet-activating factor changes in phospholipid extracts from the plasma, peripheral blood mononuclear cells and bone marrow mononuclear cells of patients with acute leukemia--a 31P MRS in vitro study. Cell Mol Biol Lett; 2008;13(1):58-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platelet-activating factor changes in phospholipid extracts from the plasma, peripheral blood mononuclear cells and bone marrow mononuclear cells of patients with acute leukemia--a 31P MRS in vitro study.
  • The aim of this investigation was to evaluate the changes in PAF concentrations in the plasma, PBMC and BMMC of patients with acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML).
  • [MeSH-major] Bone Marrow Cells / metabolism. Leukemia, Myeloid, Acute / metabolism. Leukocytes, Mononuclear / metabolism. Magnetic Resonance Spectroscopy. Phospholipids / blood. Platelet Activating Factor / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Adult. Aged. Cell Differentiation / physiology. Female. Humans. Male. Middle Aged. Phosphorus Isotopes / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952375.001).
  • [ISSN] 1689-1392
  • [Journal-full-title] Cellular & molecular biology letters
  • [ISO-abbreviation] Cell. Mol. Biol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Phospholipids; 0 / Phosphorus Isotopes; 0 / Platelet Activating Factor
  •  go-up   go-down


12. Aref S, Mabed M, El-Sherbiny M, Selim T, Metwaly A: Cyclin D1 expression in acute leukemia. Hematology; 2006 Feb;11(1):31-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin D1 expression in acute leukemia.
  • BACKGROUND: Disorders of the cell cycle regulatory machinery play a key role in the pathogenesis of cancer.
  • Over expression of cyclin D1 protein has been reported in several solid tumors and certain lymphoid malignancies, but little is known about the involvement of cyclin D1 in acute leukemia.
  • PATIENTS AND METHODS: In this study, we analyzed the expression of cyclin D1 at protein level in, 40 newly diagnosed patients with acute myeloid leukemia (AML), 10 patients with acute lymphoblastic leukemia (ALL), and 11 normal controls using flow cytometry.
  • The ALL cases with cyclin D1 over expression were significantly correlated to blast cell counts in the peripheral blood and bone marrow (BM) but not with hemoglobin level, WBC, and platelets count.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Cyclin D1 / biosynthesis. Gene Expression Regulation, Leukemic. Leukemia, Myeloid, Acute / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood
  • [MeSH-minor] Adult. Bone Marrow / metabolism. Bone Marrow / pathology. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16522546.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 136601-57-5 / Cyclin D1
  •  go-up   go-down


13. Potenza L, Barozzi P, Vallerini D, Bosco R, Quadrelli C, Mediani L, Morselli M, Forghieri F, Volzone F, Codeluppi M, Rossi G, Tazzioli G, Venturelli C, Torelli G, Luppi M: Diagnosis of invasive aspergillosis by tracking Aspergillus-specific T cells in hematologic patients with pulmonary infiltrates. Leukemia; 2007 Mar;21(3):578-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Aspergillosis / diagnosis. Leukemia, Myeloid / complications. Lung Diseases, Fungal / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Th1 Cells / immunology. Th2 Cells / immunology
  • [MeSH-minor] Acute Disease. Adult. Antifungal Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Enzyme-Linked Immunosorbent Assay. Fatal Outcome. Female. Humans. Immunocompromised Host. Interferon-gamma / secretion. Interleukin-10 / secretion. Lymphoma, B-Cell / complications. Male. Middle Aged. Neutropenia / chemically induced. Neutropenia / complications. Pneumonectomy. Purpura, Thrombotic Thrombocytopenic / complications. T-Cell Antigen Receptor Specificity. Thoracic Surgery, Video-Assisted

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17215858.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 130068-27-8 / Interleukin-10; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


14. Watanabe J, Ogura K, Kobayashi S, Torikai H, Ikeda T, Sato K, Kimura F, Motoyoshi K: [HHV-6 encephalitis after unrelated cord blood transplantation in a patient with acute lymphoblastic leukemia]. Nihon Naika Gakkai Zasshi; 2005 Nov 10;94(11):2388-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [HHV-6 encephalitis after unrelated cord blood transplantation in a patient with acute lymphoblastic leukemia].
  • [MeSH-major] Cord Blood Stem Cell Transplantation / adverse effects. Herpesvirus 6, Human. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Roseolovirus Infections / etiology
  • [MeSH-minor] Adult. Female. Humans


15. Dasatinib: for some difficult cases of adult leukaemia. Prescrire Int; 2008 Aug;17(96):149-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dasatinib: for some difficult cases of adult leukaemia.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Pyrimidines / therapeutic use. Thiazoles / therapeutic use
  • [MeSH-minor] Adult. Clinical Trials as Topic. Drug Approval. Europe. Humans. Orphan Drug Production. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Protein Kinase Inhibitors / administration & dosage. Protein Kinase Inhibitors / adverse effects. Protein Kinase Inhibitors / therapeutic use

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19496239.001).
  • [ISSN] 1167-7422
  • [Journal-full-title] Prescrire international
  • [ISO-abbreviation] Prescrire Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles
  •  go-up   go-down


16. Wang D, Guo MX, Hu HM, Zhao ZZ, Qiu HL, Shao HJ, Zhu CG, Xue L, Shi YB, Li WX: Human T-cell leukemia virus type 1 oncoprotein tax represses ZNF268 expression through the cAMP-responsive element-binding protein/activating transcription factor pathway. J Biol Chem; 2008 Jun 13;283(24):16299-308
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human T-cell leukemia virus type 1 oncoprotein tax represses ZNF268 expression through the cAMP-responsive element-binding protein/activating transcription factor pathway.
  • Expression of the human T-cell leukemia virus type 1 (HTLV-1) oncoprotein Tax is correlated with cellular transformation, contributing to the development of adult T-cell leukemia.
  • In this study, we investigated the role of Tax in the regulation of the ZNF268 gene, which plays a role in the differentiation of blood cells and the pathogenesis of leukemia.
  • These findings suggest a role for ZNF268 in aberrant T-cell proliferation observed in HTLV-1-associated diseases.

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1992 Jul;66(7):4570-5 [1351105.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Feb 1;89(3):1006-10 [1736281.001]
  • [Cites] J Exp Med. 1992 Oct 1;176(4):981-9 [1402668.001]
  • [Cites] Genes Dev. 1992 Nov;6(11):2066-76 [1427072.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):610-4 [8421695.001]
  • [Cites] J Biol Chem. 1996 Jun 14;271(24):14584-90 [8662878.001]
  • [Cites] J Neurovirol. 1997 Feb;3(1):16-27 [9147818.001]
  • [Cites] Virology. 1997 Apr 28;231(1):135-40 [9143312.001]
  • [Cites] Chem Biol. 1995 Dec;2(12):819-26 [8807815.001]
  • [Cites] J Virol. 1999 Jun;73(6):4856-65 [10233947.001]
  • [Cites] J Virol. 1999 Oct;73(10):7981-7 [10482545.001]
  • [Cites] Int J Mol Med. 2004 Dec;14(6):971-5 [15547661.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:620-42 [15569604.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55127-36 [15496409.001]
  • [Cites] Retrovirology. 2004;1:20 [15310405.001]
  • [Cites] Int J Mol Med. 2006 Sep;18(3):457-63 [16865230.001]
  • [Cites] J Biol Chem. 2006 Aug 25;281(34):24623-36 [16787922.001]
  • [Cites] Mol Endocrinol. 2000 Sep;14(9):1448-61 [10976922.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(3):928-39 [11154279.001]
  • [Cites] J Virol. 2001 Mar;75(5):2161-73 [11160720.001]
  • [Cites] Biochim Biophys Acta. 2001 Apr 16;1518(3):306-10 [11311945.001]
  • [Cites] Blood. 2002 Sep 15;100(6):2123-31 [12200376.001]
  • [Cites] IUBMB Life. 2003 Mar;55(3):127-31 [12822888.001]
  • [Cites] J Biol Chem. 2003 Aug 8;278(32):29394-9 [12734192.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5131-40 [12910250.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Nov;77(11):6815-9 [6256763.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Virology. 1985 Nov;147(1):223-6 [2998067.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Feb;87(3):1071-5 [2300570.001]
  • [Cites] Genes Dev. 1990 Nov;4(11):1875-85 [2276622.001]
  • [Cites] Oncogene. 1991 Apr;6(4):543-51 [1827666.001]
  • [Cites] Oncogene. 1991 Jun;6(6):1023-9 [1906155.001]
  • [Cites] J Biol Chem. 1991 Sep 15;266(26):17531-6 [1894635.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11445-9 [1763059.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7070-4 [1386673.001]
  • (PMID = 18375384.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Activating Transcription Factor 1; 0 / CREB1 protein, human; 0 / Cyclic AMP Response Element-Binding Protein; 0 / DNA-Binding Proteins; 0 / Gene Products, tax; 0 / Repressor Proteins; 0 / ZNF268 protein, human; E0399OZS9N / Cyclic AMP
  • [Other-IDs] NLM/ PMC2423250
  •  go-up   go-down


17. Yasunaga J, Matsuoka M: Human T-cell leukemia virus type I induces adult T-cell leukemia: from clinical aspects to molecular mechanisms. Cancer Control; 2007 Apr;14(2):133-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human T-cell leukemia virus type I induces adult T-cell leukemia: from clinical aspects to molecular mechanisms.
  • BACKGROUND: Human T-cell leukemia virus type I (HTLV-I) is a causative virus of adult T-cell leukemia (ATL), HTLV-I-associated myelopathy/tropical spastic paraparesis, and HTLV-I-associated uveitis.
  • Effectiveness of allogeneic stem cell transplantation for ATL has been recently reported.
  • [MeSH-major] CD4-Positive T-Lymphocytes / virology. Human T-lymphotropic virus 1 / pathogenicity. Leukemia-Lymphoma, Adult T-Cell / virology
  • [MeSH-minor] Adult. Anti-Retroviral Agents / therapeutic use. Antibodies, Monoclonal / therapeutic use. Gene Expression Regulation, Viral. Genes, pX. Humans. NF-kappa B / antagonists & inhibitors. Viral Proteins / genetics

  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17387298.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Antibodies, Monoclonal; 0 / NF-kappa B; 0 / Viral Proteins
  • [Number-of-references] 79
  •  go-up   go-down


18. Magro CM, Dyrsen ME: Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B- and T-cell lymphoid infiltrates. J Cutan Pathol; 2008 Nov;35(11):1040-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B- and T-cell lymphoid infiltrates.
  • DESIGN: We investigated the expression of CLA using the HECA-452 antibody on paraffin-embedded, formalin-fixed tissue in a variety of reactive, neoplastic and preneoplastic cutaneous lymphoid infiltrates of T- and B-cell derivation.
  • High levels of CLA expression were seen in epidermotropic T-cell dyscrasias and epidermotropic T-cell lymphomas including mycosis fungoides (MF) and adult T-cell leukemia/lymphoma (ATCLL).
  • A loss of CLA in tumors normally positive for CLA was a feature of disease progression best exemplified by tumor-stage MF and acute ATCLL.
  • There was a lack of CLA expression in those lymphocytic infiltrates manifesting subcutaneous localization including lupus profundus, panniculitis-like T-cell lymphoma and atypical lymphocytic lobular panniculitis.
  • CLA expression was not only observed in primary cutaneous anaplastic large cell lymphoma but also seen in cases of nodal anaplastic large cell lymphoma secondarily involving the skin and was negative in cases of nodal anaplastic large cell lymphoma without any established skin involvement.
  • CLA was negative in the majority of B-cell lymphomas.
  • CONCLUSIONS: CLA plays a role in the pattern of T-cell lymphocyte migration in the skin and subcutis in both reactive and neoplastic states.
  • An alteration in the expression of this marker, whether it is in the context of the acquisition of expression in a cell that is normally CLA negative or its loss of expression, may define a key event in determining cutaneous and extracutaneous hematopoietic cell distribution.
  • [MeSH-major] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Dermatitis / immunology. Lymphoma, B-Cell / immunology. Lymphoma, T-Cell / immunology. Lymphoma, T-Cell, Cutaneous / immunology. Skin Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18681860.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  •  go-up   go-down


19. Lee E, Park HJ, Cho BK, Lee JY, Lee S: Leukemia cutis as early relapse of T-cell acute lymphoblastic leukemia. Int J Dermatol; 2010 Mar;49(3):335-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia cutis as early relapse of T-cell acute lymphoblastic leukemia.
  • [MeSH-major] Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / therapy. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Humans. Male. Recurrence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20465677.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


20. Jeang KT: Human T cell leukemia virus type 1 (HTLV-1) and oncogene or oncomiR addiction? Oncotarget; 2010 Oct;1(6):453-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human T cell leukemia virus type 1 (HTLV-1) and oncogene or oncomiR addiction?
  • The mechanism of HTLV-1 transformation of cells to Adult T cell leukemia (ATL) remains not fully understood.
  • [MeSH-minor] Adult. HTLV-I Infections / genetics. HTLV-I Infections / virology. Humans

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2005 Sep 5;24(39):6058-68 [16155612.001]
  • [Cites] Nat Med. 2006 Apr;12(4):466-72 [16550188.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Aug;3(8):448-57 [16894390.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] Nat Med. 2007 May;13(5):527-8 [17479090.001]
  • [Cites] J Cell Biochem. 2007 Oct 15;102(3):531-8 [17661351.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16170-5 [17911264.001]
  • [Cites] Retrovirology. 2007;4:82 [18036240.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8976-85 [18974142.001]
  • [Cites] Retrovirology. 2008;5:100 [19014482.001]
  • [Cites] Blood. 2009 May 14;113(20):4914-7 [19246560.001]
  • [Cites] Virus Res. 2009 Aug;143(2):195-208 [19540281.001]
  • [Cites] Nat Rev Genet. 2009 Oct;10(10):704-14 [19763153.001]
  • [Cites] Genes Dev. 2009 Dec 1;23(23):2700-4 [19903759.001]
  • [Cites] Retrovirology. 2009;6:117 [20017952.001]
  • [Cites] Retrovirology. 2010;7:17 [20222966.001]
  • [Cites] J Biol Chem. 2010 Aug 6;285(32):24707-16 [20529860.001]
  • [Cites] Mol Aspects Med. 2010 Oct;31(5):367-82 [20600265.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):559-67 [14991578.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] Nature. 1990 Nov 15;348(6298):245-8 [2146511.001]
  • [Cites] Int Immunol. 1991 Aug;3(8):761-7 [1911545.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1057-61 [7862633.001]
  • [Cites] J Biol Chem. 1998 Mar 20;273(12):6698-703 [9506967.001]
  • [Cites] Cell. 1998 Apr 3;93(1):81-91 [9546394.001]
  • [Cites] J Virol. 1999 Jun;73(6):4856-65 [10233947.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Retrovirology. 2005;2:17 [15743526.001]
  • [Cites] Retrovirology. 2005;2:16 [15743528.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5931-7 [16155600.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • (PMID = 21311101.001).
  • [ISSN] 1949-2553
  • [Journal-full-title] Oncotarget
  • [ISO-abbreviation] Oncotarget
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 AI001023-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / MicroRNAs
  • [Other-IDs] NLM/ NIHMS242806; NLM/ PMC3058865
  •  go-up   go-down


21. Bardini M, Spinelli R, Bungaro S, Mangano E, Corral L, Cifola I, Fazio G, Giordan M, Basso G, De Rossi G, Biondi A, Battaglia C, Cazzaniga G: DNA copy-number abnormalities do not occur in infant ALL with t(4;11)/MLL-AF4. Leukemia; 2010 Jan;24(1):169-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathogenesis of infant acute lymphoblastic leukemia (ALL) is still not well defined.
  • Short latency to leukemia and very high concordance rate for ALL in Mixed-Lineage Leukemia (MLL)-positive infant twins suggest that the MLL rearrangement itself could be sufficient for overt leukemia.
  • Attempts to generate a suitable mouse model for MLL-AF4-positive ALL did not thoroughly resolve the issue of whether cooperating mutations are required to reduce latency and to generate overt leukemia in vivo.
  • In contrast to pediatric, adolescent and adult ALL cases, the MLL rearrangement in infant ALL is associated with an exceptionally low frequency of copy-number abnormalities, thus confirming the unique nature of this disease.
  • It can be argued that the MLL rearrangement as a first hit, rather than inducing the acquisition of additional genetic lesions, has a major role to drive and hasten the onset of leukemia.
  • [MeSH-major] Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 4. Gene Dosage. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic

  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19907438.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MLL-AF4 fusion protein, human; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  •  go-up   go-down


22. Au WY, Chan E, Lie AK: Hemopoietic stem cell transplantation from a donor with indeterminate HTLV-1 status. Am J Hematol; 2007 Jun;82(6):495
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemopoietic stem cell transplantation from a donor with indeterminate HTLV-1 status.
  • [MeSH-major] HTLV-I Infections / prevention & control. Hematopoietic Stem Cell Transplantation / adverse effects. Human T-lymphotropic virus 1 / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Tissue Donors
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Benzamides. Blotting, Western. Female. Follow-Up Studies. Humans. Imatinib Mesylate. Piperazines / therapeutic use. Polymerase Chain Reaction. Pyrimidines / therapeutic use. Recurrence. Remission Induction. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929539.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


23. Song JH, Kim HJ, Lee CH, Kim SJ, Hwang SY, Kim TS: Identification of gene expression signatures for molecular classification in human leukemia cells. Int J Oncol; 2006 Jul;29(1):57-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of gene expression signatures for molecular classification in human leukemia cells.
  • Although the methods by which leukemia is classified have been improved for effective therapies, leukemia patients occasionally exhibit diverse, sometimes unpredictable, responses to treatment.
  • Consequently, these patients also evidence individually different clinical courses when administered with anti-leukemia drugs.
  • In order to find new, more precise molecular markers for leukemia classification, we have analyzed the gene expression profiles from 65 diagnostic bone marrow specimens of adult patients with AML, ALL, CML or CLL by using high-throughput DNA microarrays harboring approximately 8,300 unique human genes or expression sequence tags.
  • In the present study, we identified a group of leukemia-specific genes, which manifest gene expression profiles distinctly representative of normal bone marrow samples, as determined by a significance analysis of microarray (SAM) and GeneSpring 6.1 programs.
  • We also determined the minimal number of genes showing a difference between acute and chronic leukemia patient groups.
  • Our results may provide a novel set of molecular criteria for the classification of leukemia patients, and may also facilitate effects to discovery new targets, allowing for more effective treatment of leukemia patients.
  • [MeSH-major] Biomarkers, Tumor / analysis. Bone Marrow Cells / metabolism. Gene Expression Profiling. Gene Expression Regulation, Leukemic. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Myeloid, Acute / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD / genetics. Antigens, CD / metabolism. Antigens, Differentiation, T-Lymphocyte / genetics. Antigens, Differentiation, T-Lymphocyte / metabolism. Biopsy. Cluster Analysis. Female. Genetic Markers. Homeodomain Proteins / genetics. Homeodomain Proteins / metabolism. Humans. Lectins, C-Type. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Phosphatidylinositol 3-Kinases / genetics. Phosphatidylinositol 3-Kinases / metabolism. Transcription Factors / genetics. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16773185.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Biomarkers, Tumor; 0 / CD69 antigen; 0 / Genetic Markers; 0 / HHEX protein, human; 0 / Homeodomain Proteins; 0 / Lectins, C-Type; 0 / Transcription Factors; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human
  •  go-up   go-down


24. Taylor JM, Brown M, Nejmeddine M, Kim KJ, Ratner L, Lairmore M, Nicot C: Novel role for interleukin-2 receptor-Jak signaling in retrovirus transmission. J Virol; 2009 Nov;83(22):11467-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-lymphotropic virus type 1 (HTLV-1) is the etiological agent of adult T-cell leukemia/lymphoma, and it encodes a number of nonstructural proteins that are involved in virus replication and immune evasion.
  • Using a previously established T-cell line immortalized with an HTLV-1 molecular clone deleted for p12, we assessed the role of p12 in regulating cellular growth and virus transmission.
  • Consistently with previous studies, p12- and p12+ cell lines produced similar amounts of virus particles released into the supernatant of cultured cells, although we found that p12 expression greatly enhanced virus transmission.
  • Intriguingly, IL-2/Jak signaling was not associated with changes in viral gene expression, viral RNA encapsidation, the maturation of the virus particle, cell-cell adherence, or Gag polarization and virological synapse formation.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2007 Sep;81(17):9088-99 [17582004.001]
  • [Cites] J Virol. 2007 Sep;81(18):9707-17 [17609265.001]
  • [Cites] J Natl Cancer Inst. 2008 Jan 16;100(2):98-108 [18182620.001]
  • [Cites] Nat Med. 2008 Apr;14(4):429-36 [18376405.001]
  • [Cites] J Virol. 2008 Jul;82(14):7135-43 [18480461.001]
  • [Cites] Retrovirology. 2008;5:105 [19032754.001]
  • [Cites] Blood. 2009 Jul 30;114(5):1016-25 [19494354.001]
  • [Cites] Nature. 1988 Oct 20;335(6192):738-40 [3262832.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(18):7329-33 [1976256.001]
  • [Cites] J Virol. 1992 Feb;66(2):906-13 [1530980.001]
  • [Cites] J Virol. 1992 Mar;66(3):1737-45 [1310774.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3005-9 [1348363.001]
  • [Cites] J Virol. 1992 Jul;66(7):4601-5 [1602562.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8813-7 [1528897.001]
  • [Cites] J Immunol. 1992 Nov 1;149(9):2879-86 [1401919.001]
  • [Cites] J Virol. 1993 Mar;67(3):1590-9 [8382312.001]
  • [Cites] J Virol. 1993 Dec;67(12):7701-4 [8230493.001]
  • [Cites] Int J Cancer. 1995 Feb 8;60(4):554-61 [7530239.001]
  • [Cites] J Virol Methods. 1995 Jan;51(1):19-29 [7730434.001]
  • [Cites] Science. 1995 Jul 7;269(5220):79-81 [7604283.001]
  • [Cites] J Clin Invest. 1995 Sep;96(3):1548-55 [7657825.001]
  • [Cites] Oncogene. 1995 Sep 7;11(5):993-8 [7675460.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3619-39 [7579327.001]
  • [Cites] J Cell Sci. 2000 Jan;113 ( Pt 1):37-44 [10591623.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):567-72 [10662802.001]
  • [Cites] Blood. 2000 Jul 1;96(1):275-81 [10891462.001]
  • [Cites] Virology. 2000 Aug 15;274(1):86-93 [10936091.001]
  • [Cites] J Virol. 2000 Nov;74(21):9828-35 [11024109.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1777-81 [11080826.001]
  • [Cites] J Virol. 2001 Aug;75(16):7351-61 [11462007.001]
  • [Cites] Blood. 2001 Aug 1;98(3):823-9 [11468184.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1200-8 [11493471.001]
  • [Cites] J Virol. 2002 Apr;76(7):3493-501 [11884573.001]
  • [Cites] J Virol. 2002 May;76(10):4709-22 [11967288.001]
  • [Cites] J Virol. 2002 Aug;76(16):8485-93 [12134053.001]
  • [Cites] Microbiol Mol Biol Rev. 2002 Sep;66(3):396-406, table of contents [12208996.001]
  • [Cites] Science. 2003 Mar 14;299(5613):1713-6 [12589003.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):226-37, table of contents [12794191.001]
  • [Cites] J Virol. 2003 Oct;77(20):11027-39 [14512551.001]
  • [Cites] Nat Med. 2004 Feb;10(2):197-201 [14730358.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):31991-4 [15090550.001]
  • [Cites] J Cell Sci. 2004 Aug 1;117(Pt 17):3983-93 [15286176.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2852-9 [15353320.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2523-31 [15226182.001]
  • [Cites] J Exp Med. 1973 Feb 1;137(2):387-410 [4568301.001]
  • [Cites] Nature. 1981 Nov 19;294(5838):268-71 [6272125.001]
  • [Cites] Int J Cancer. 1983 Sep 15;32(3):321-8 [6604033.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Dec;80(23):7337-41 [6316359.001]
  • [Cites] Cell. 1987 Jan 30;48(2):343-50 [3026643.001]
  • [Cites] Cell. 1987 Apr 10;49(1):47-56 [3030566.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Aug;84(15):5389-93 [3037548.001]
  • [Cites] Science. 1996 Apr 12;272(5259):263-7 [8602510.001]
  • [Cites] J Virol. 1997 Jan;71(1):259-66 [8985345.001]
  • [Cites] J Virol. 1997 Feb;71(2):1173-80 [8995639.001]
  • [Cites] J Virol. 1997 Jun;71(6):4445-51 [9151835.001]
  • [Cites] Virology. 1997 Oct 13;237(1):123-8 [9344914.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13897-902 [9391124.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3845-50 [9520455.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4701-7 [9616168.001]
  • [Cites] J Gen Virol. 1999 Jun;80 ( Pt 6):1429-36 [10374960.001]
  • [Cites] J Virol. 1999 Nov;73(11):9642-9 [10516077.001]
  • [Cites] AIDS Res Hum Retroviruses. 2005 Jan;21(1):43-50 [15665643.001]
  • [Cites] J Exp Med. 2005 Feb 7;201(3):419-30 [15699074.001]
  • [Cites] Blood. 2005 Aug 1;106(3):988-95 [15831709.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1169-74 [15902300.001]
  • [Cites] J Biol Chem. 2005 Aug 19;280(33):29653-60 [15975923.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6026-34 [16155609.001]
  • [Cites] J Immunol. 2006 May 1;176(9):5463-70 [16622014.001]
  • [Cites] J Virol. 2006 May;80(10):4771-80 [16641270.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1021-9 [16569765.001]
  • (PMID = 19726513.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA115398; United States / NCI NIH HHS / CA / P01 CA100730-07; United States / NCI NIH HHS / CA / CA100730; United States / NCI NIH HHS / CA / CA63417; United States / NCI NIH HHS / CA / CA10521; United States / NCI NIH HHS / CA / CA106258; United States / NCI NIH HHS / CA / CA70529; United States / NCI NIH HHS / CA / R01 CA063417; United States / NCI NIH HHS / CA / CA100730-07; United States / NCI NIH HHS / CA / P01 CA100730; United States / NCI NIH HHS / CA / CA115398; United States / NCI NIH HHS / CA / R01 CA106258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 0 / Receptors, Interleukin-2; 0 / Retroviridae Proteins, Oncogenic; 0 / STAT Transcription Factors; 0 / Viral Regulatory and Accessory Proteins; 0 / p12I protein, Human T-lymphotropic virus 1; EC 2.7.10.2 / Janus Kinases
  • [Other-IDs] NLM/ PMC2772716
  •  go-up   go-down


25. Fujii N, Ikeda K, Koyama M, Aoyama K, Masunari T, Kondo E, Matsuzaki T, Mizobuchi S, Hiraki A, Teshima T, Shinagawa K, Ishimaru F, Tanimoto M: Calcineurin inhibitor-induced irreversible neuropathic pain after allogeneic hematopoietic stem cell transplantation. Int J Hematol; 2006 Jun;83(5):459-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcineurin inhibitor-induced irreversible neuropathic pain after allogeneic hematopoietic stem cell transplantation.
  • We report a case of irreversible CI-induced neuropathic pain following allogeneic hematopoietic stem cell transplantation.
  • [MeSH-major] Calcineurin Inhibitors. Cyclosporine / adverse effects. Hematopoietic Stem Cell Transplantation. Immunosuppressive Agents / adverse effects. Pain / chemically induced. Peripheral Nervous System Diseases / chemically induced. Tacrolimus / adverse effects
  • [MeSH-minor] Adult. Female. Graft vs Host Disease / diagnostic imaging. Graft vs Host Disease / prevention & control. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnostic imaging. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Radiography. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol. 1999 May;246(5):339-46 [10399863.001]
  • [Cites] Arthritis Rheum. 1991 May;34(5):625-30 [2025314.001]
  • [Cites] Ann Intern Med. 1994 Dec 1;121(11):863-5 [7978699.001]
  • [Cites] Ann Neurol. 1996 Nov;40(5):750-8 [8957016.001]
  • [Cites] Br J Haematol. 2003 Oct;123(1):110-3 [14510951.001]
  • [Cites] Transpl Int. 2000;13(5):313-26 [11052266.001]
  • [Cites] Bone Marrow Transplant. 1996 Jul;18(1):157-62 [8832009.001]
  • [Cites] Br J Haematol. 2004 Aug;126(3):288 [15257699.001]
  • [Cites] Clin Exp Rheumatol. 1994 Nov-Dec;12 (6):653-6 [7895401.001]
  • [Cites] N Engl J Med. 1991 Nov 14;325(20):1449-50 [1922263.001]
  • [Cites] Transpl Int. 2001;14 (1):16-23 [11263551.001]
  • [Cites] Pathol Oncol Res. 2004;10(4):204-6 [15619640.001]
  • [Cites] Transpl Int. 1998;11 Suppl 1:S331-3 [9665009.001]
  • (PMID = 16787880.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Calcineurin Inhibitors; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


26. Retraction. Tanji H, Ishikawa C, Sawada S, Nakachi S, Takamatsu R, Matsuda T, Okudaira T, Uchihara J-N, Ohshiro K, Tanaka Y, Senba M, Uezato H, Ohshima K, Duc Dodon M, Wu K-J, Mori N. Aberrant expression of the transcription factor Twist in adult T-cell leukemia [published online ahead of print January 13, 2010]. Blood. doi:10.1182/blood-2009-07-232231. Blood; 2010 Aug 26;116(8):1386
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retraction. Tanji H, Ishikawa C, Sawada S, Nakachi S, Takamatsu R, Matsuda T, Okudaira T, Uchihara J-N, Ohshiro K, Tanaka Y, Senba M, Uezato H, Ohshima K, Duc Dodon M, Wu K-J, Mori N. Aberrant expression of the transcription factor Twist in adult T-cell leukemia [published online ahead of print January 13, 2010]. Blood. doi:10.1182/blood-2009-07-232231.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionOf] Tanji H, Ishikawa C, Sawada S, Nakachi S, Takamatsu R, Matsuda T, Okudaira T, Uchihara JN, Ohshiro K, Tanaka Y, Senba M, Uezato H, Ohshima K, Duc Dodon M, Wu KJ, Mori N. Blood. 2010 Jan 13;. doi: 10.1182/blood-2009-07-232231 [20071663.001]
  • (PMID = 20574045.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Retraction of Publication
  • [Publication-country] United States
  •  go-up   go-down


27. Kubuki Y, Suzuki M, Sasaki H, Toyama T, Yamashita K, Maeda K, Ido A, Matsuoka H, Okayama A, Nakanishi T, Tsubouchi H: Telomerase activity and telomere length as prognostic factors of adult T-cell leukemia. Leuk Lymphoma; 2005 Mar;46(3):393-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase activity and telomere length as prognostic factors of adult T-cell leukemia.
  • The study was carried out in 22 patients with adult T-cell leukemia (ATL) (7 chronic and 15 acute types) and in 13 asymptomatic human T-lymphotropic virus type 1 (HTLV-1) carriers.
  • The mean values of TA in acute and chronic type patients were 13.8 and 1.6 total product generated (TPG) units, respectively, as determined by telomeric repeat amplification assays.
  • The mean TA value in acute type patients was significantly higher than in the three other subject groups.
  • The mean TL values in patients with acute and chronic types were 5.39 and 4.38 Kb, respectively, while the mean TL values in HTLV-1 carriers and healthy volunteers were 7.69 and 7.06 Kb, respectively.
  • Neither TA nor TL of ATL cells showed any significant association with the number of ATL cells, serum soluble interleukin-2 receptor, or serum lactate dehydrogenase in the peripheral blood of acute type patients.
  • The median survival period of acute ATL patients with high TA and shortened TL was 0.47 years, however, which was significantly shorter than that of acute ATL patients with low TA and normal TL (4.21 years) (p < 0.002).
  • [MeSH-major] HTLV-I Infections / enzymology. Leukemia-Lymphoma, Adult T-Cell / enzymology. Telomerase / metabolism. Telomere / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Leukocytes, Mononuclear / chemistry. Leukocytes, Mononuclear / enzymology. Male. Middle Aged. Prognosis. Prospective Studies. Restriction Mapping. Serologic Tests. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621829.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


28. Nicot C: Current views in HTLV-I-associated adult T-cell leukemia/lymphoma. Am J Hematol; 2005 Mar;78(3):232-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current views in HTLV-I-associated adult T-cell leukemia/lymphoma.
  • HTLV-I is the etiological agent of adult T-cell leukemia/lymphoma (ATLL) and is also associated with cutaneous T-cell lymphoma (CTCL).
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726602.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI058944; United States / NCI NIH HHS / CA / R01 CA106258
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 126
  •  go-up   go-down


29. Ravandi F, Faderl S: Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin. Leuk Res; 2006 Jan;30(1):103-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin.
  • Treatment of adult T-cell leukemia (ATL) remains difficult.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia-Lymphoma, Adult T-Cell / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15979704.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 395575MZO7 / Pentostatin; 3A189DH42V / alemtuzumab
  •  go-up   go-down


30. Wei W, Yang R, Guo T, Yang Y, Hu Y: Fribrinolysis kinetics and its application. J Huazhong Univ Sci Technolog Med Sci; 2007 Feb;27(1):111-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There was significant difference in fibrinolysis kinetics and plasma plasminogen concentration between 22 normal subjects and 27 patients with acute myeloblastic leukemia (P<0.05 and <0.01 respectively).
  • [MeSH-major] Clinical Protocols. Fibrinolysis / physiology. Leukemia, Myeloid, Acute / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood
  • [MeSH-minor] Adolescent. Adult. Blood Coagulation / drug effects. Case-Control Studies. Cell Line, Tumor. Crotalid Venoms / analysis. Crotalid Venoms / metabolism. Crotalid Venoms / pharmacology. Drug Monitoring. Female. Fibrinogen / analysis. Fibrinogen / metabolism. Humans. Kinetics. Male. Middle Aged. Ovarian Neoplasms / blood. Ovarian Neoplasms / pathology. Reproducibility of Results. Spectrophotometry, Ultraviolet. Thrombin / analysis. Thrombin / metabolism. Thrombin / pharmacology. Time Factors. Transfection. Urokinase-Type Plasminogen Activator / analysis. Urokinase-Type Plasminogen Activator / metabolism. Urokinase-Type Plasminogen Activator / pharmacology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17393125.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Crotalid Venoms; 9001-32-5 / Fibrinogen; EC 3.4.21.5 / Thrombin; EC 3.4.21.5 / acutobin, Deinagkistrodon acutus; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


31. Schrøder H, Kjeldahl M, Boesen AM, Nielsen OJ, Schmidt K, Johnsen HE, Gregersen H, Heyman M, Gustafsson G: Acute lymphoblastic leukemia in adolescents between 10 and 19 years of age in Denmark--secondary publication. Dan Med Bull; 2006 Feb;53(1):76-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia in adolescents between 10 and 19 years of age in Denmark--secondary publication.
  • INTRODUCTION: Data seem to indicate that young adults with acute lymphoblastic leukemia (ALL) have a better survival when treated with pediatric protocols compared with adult ALL protocols.
  • RESULTS: There were no difference with respect to the distribution of T-ALL, CNS-leukemia, total white blood count and high risk chromosomal abnormalities between the two groups.
  • CONCLUSION: Young adult patients with ALL might benefit from therapy with pediatric NOPHO ALL protocols.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Daunorubicin / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Methotrexate / administration & dosage. Neoplasm Recurrence, Local. Prednisone / administration & dosage. Prognosis. Retrospective Studies. Stem Cell Transplantation. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16761337.001).
  • [ISSN] 1603-9629
  • [Journal-full-title] Danish medical bulletin
  • [ISO-abbreviation] Dan Med Bull
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


32. Hoshino T, Tahara K, Miyawaki K, Hatsumi N, Takada S, Miyawaki S, Sakura T: [Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib]. Rinsho Ketsueki; 2010 Mar;51(3):181-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib].
  • We retrospectively analyzed the clinical outcome of dasatinib in 7 patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) resistant or intolerant to imatinib.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage. Thiazoles / administration & dosage
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colitis / chemically induced. Colitis / virology. Cytomegalovirus Infections. Dasatinib. Humans. Middle Aged. Pleural Effusion / chemically induced. Retrospective Studies. Treatment Outcome


33. Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, Ikeda S, Masuda M, Nagoshi H, Ueda R, Tamura K, Sano M, Momita S, Yamaguchi K, Kawano F, Hanada S, Tobinai K, Shimoyama M, Hotta T, Tomonaga M, Japan Clinical Oncology Group Study JCOG9801: VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol; 2007 Dec 1;25(34):5458-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.
  • PURPOSE: Our previous phase II trial for treating human T-lymphotropic virus type I-associated adult T-cell leukemia-lymphoma (ATLL) with vincristine, cyclophosphamide, doxorubicin, and prednisone (VCAP), doxorubicin, ranimustine, and prednisone (AMP), and vindesine, etoposide, carboplatin, and prednisone (VECP) showed promising results.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Middle Aged. Nitrosourea Compounds / administration & dosage. Prednisone / administration & dosage. Survival Rate. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17968021.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; RYH2T97J77 / ranimustine; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


34. Tomita M, Tanaka Y, Mori N: Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV-1-infected T lymphocytes in vitro. Int J Cancer; 2010 Oct 1;127(7):1584-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aurora kinases play an essential role in regulating mitosis and cell division.
  • Inhibition of Aurora kinases results in suppression of cell division, phosphorylation of histone H3 and induction of apoptosis in many cell types.
  • In our study, we report the in vitro activities of AZD1152, a selective inhibitor of Aurora B kinase in human T-cell leukemia virus type 1 (HTLV-1), the causative agent of adult T-cell leukemia (ATL), -infected T-cell lines.
  • Overexpression of Aurora B was noted in HTLV-1-infected T-cell lines compared to HTLV-1-uninfected T-cell lines.
  • AZD1152 reduced the viability of HTLV-1-infected T-cell lines within 24 hr but did not affect that of -uninfected T-cell lines.
  • Although AZD1152 inhibited phosphorylation of histone H3 on Ser10 in both HTLV-1-infected and -uninfected T-cell lines, it induced polyploidy only in HTLV-1-uninfected T-cell lines.
  • We have reported previously that a pan-Aurora kinase inhibitor induced apoptosis through inhibition of NF-kappaB signaling activity in HTLV-1-infected T-cell lines.
  • It induced p53 and p21 expression in HTLV-1-infected but not in HTLV-1-uninfected T-cell lines, suggesting that activation of p53-dependent postmitotic checkpoint might prevent polyploidy in HTLV-1-infected T-cells.
  • [MeSH-major] Cell Survival / drug effects. Human T-lymphotropic virus 1 / pathogenicity. Organophosphates / pharmacology. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Quinazolines / pharmacology. T-Lymphocytes / virology
  • [MeSH-minor] Aurora Kinase B. Aurora Kinases. B-Lymphocytes / cytology. B-Lymphocytes / drug effects. Cell Cycle / drug effects. Cell Division / drug effects. Enzyme Inhibitors / pharmacology. Humans. Jurkat Cells / drug effects. Jurkat Cells / pathology. NF-kappa B / drug effects. NF-kappa B / physiology. RNA, Small Interfering / genetics. Transfection

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Int J Cancer. 2011 Dec 1;129(11):2762-3 [21960263.001]
  • (PMID = 20091867.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate; 0 / Enzyme Inhibitors; 0 / NF-kappa B; 0 / Organophosphates; 0 / Quinazolines; 0 / RNA, Small Interfering; EC 2.7.11.1 / AURKB protein, human; EC 2.7.11.1 / Aurora Kinase B; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


35. Yasunami T, Wang YH, Tsuji K, Takanashi M, Yamada Y, Motoji T: Multidrug resistance protein expression of adult T-cell leukemia/lymphoma. Leuk Res; 2007 Apr;31(4):465-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidrug resistance protein expression of adult T-cell leukemia/lymphoma.
  • In adult T-cell leukemia/lymphoma (ATL), it is difficult to achieve remission and the reason for the resistance to chemotherapeutic agents may be linked to the presence of multidrug resistance (MDR) proteins.
  • [MeSH-major] Drug Resistance, Multiple. Gene Expression Regulation, Leukemic. Gene Expression Regulation, Neoplastic. Leukemia-Lymphoma, Adult T-Cell / metabolism. Multidrug Resistance-Associated Proteins / metabolism. P-Glycoprotein / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / pharmacology. Doxorubicin / pharmacology. Drug Resistance, Neoplasm. Female. Flow Cytometry. Humans. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134750.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; 0 / multidrug resistance-associated protein 1; 80168379AG / Doxorubicin
  •  go-up   go-down


36. Sancho JM, Ribera JM, Oriol A, Hernandez-Rivas JM, Rivas C, Bethencourt C, Parody R, Deben G, Bello JL, Feliu E, Programa para el Estudio y Tratamiento de Hemopatias Malignas Group: Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer; 2006 Jun 15;106(12):2540-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis.
  • Recurrence of acute lymphoblastic leukemia (ALL) in the central nervous system (CNS) confers a poor prognosis, although to the authors' knowledge, only a few studies have analyzed this issue in adults.
  • For the current study, the authors analyzed the frequency, predictive factors, and prognosis of CNS involvement and recurrence in adult patients with ALL who did not receive cranial irradiation for CNS prophylaxis.
  • Four hundred sixty-seven adult patients (age > or = 15 years) with ALL were treated on 4 protocols: ALL-89 (standard-risk and high-risk ALL; n = 108 patients), ALL-93 (high-risk ALL; n = 222 patients), ALL-96 (standard-risk ALL; n = 84 patients), and ALL3-97 (Burkitt leukemia; n = 53 patients).
  • The only 2 survivors underwent stem cell transplantation.
  • The frequency of CNS recurrence in adult patients with ALL who do not receive radiotherapy for CNS prophylaxis was similar to the frequency observed in protocols that included cranial irradiation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Cytarabine / administration & dosage. Female. Humans. Hydrocortisone / administration & dosage. Incidence. Lactate Dehydrogenases / analysis. Male. Methotrexate / administration & dosage. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16700036.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; EC 1.1.- / Lactate Dehydrogenases; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


37. Xu B, Song X, Yip NC, Xiao P, Zhang Y, Wang W, Zhou S: Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia. Hematology; 2010 Apr;15(2):74-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia.
  • The interaction between Wilms tumor gene 1 (WT1) and the promoter region of the multidrug resistance-1 (MDR1) gene has been previously reported but the clinical significance of the coexpression of WT1 and MDR1 in acute lymphoblastic leukemia (ALL) is still largely unknown.
  • In this study, the expression levels of WT1 and MDR1 mRNA in 57 adult ALL patients were simultaneously detected using multiplex fluorescence real-time quantitative polymerase chain reaction.
  • The expression levels of WT1 and MDR1 in bone marrow samples of adult ALL patients were significantly higher than those in the normal samples (P<0.001), and in addition, the expression levels of WT1 and MDR1 mRNA were highly correlated (r(s)=0.404, P=0.002).
  • High-WT1/high-MDR1 mRNA expression was strongly associated with BCR-ABL expression and a higher tendency to be T-cell ALL type.
  • [MeSH-major] Biomarkers, Tumor / analysis. Bone Marrow / chemistry. Gene Expression Regulation, Leukemic. Genes, Wilms Tumor. Neoplasm Proteins / analysis. P-Glycoprotein / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. WT1 Proteins / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cohort Studies. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Resistance, Neoplasm / genetics. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged. P-Glycoproteins. Prognosis. RNA, Messenger / biosynthesis. RNA, Neoplasm / biosynthesis. Remission Induction. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20423567.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / WT1 Proteins; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; CVAD protocol
  •  go-up   go-down


38. Yamasaki M, Fujita S, Ishiyama E, Mukai A, Madhyastha H, Sakakibara Y, Suiko M, Hatakeyama K, Nemoto T, Morishita K, Kataoka H, Tsubouchi H, Nishiyama K: Soy-derived isoflavones inhibit the growth of adult T-cell leukemia cells in vitro and in vivo. Cancer Sci; 2007 Nov;98(11):1740-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soy-derived isoflavones inhibit the growth of adult T-cell leukemia cells in vitro and in vivo.
  • Adult T-cell leukemia occurs in human T-lymphotropic virus type I-infected individuals and is endemic to the south-western area of Kyushu in Japan.
  • In this communication, we examined the effect of soy isoflavones on the growth of adult T-cell leukemia cells in vitro and in vivo.
  • Among the isoflavones studied, genistein had the highest growth-inhibitory effect; however, genistein did not exert an apparent growth-inhibitory effect on Jurkat and Molt-4 cells, which were non-adult T-cell leukemia cells.
  • The in vivo studies demonstrated that soy-derived isoflavones significantly inhibit ED-40515 cell growth and infiltration into various organs in non-obese diabetic severe combined-immunodeficiency common gamma-chain knockout mice.
  • Taken together, it is evident that soy isoflavones might serve as a promising compound for the treatment of adult T-cell leukemia.
  • [MeSH-major] Isoflavones / pharmacology. Isoflavones / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Soybeans
  • [MeSH-minor] Animals. Cell Cycle / drug effects. Cell Division / drug effects. Cell Line, Tumor. Genistein / pharmacology. Humans. Jurkat Cells. Mice. Mice, Knockout. Mice, SCID. Transplantation, Heterologous

  • Hazardous Substances Data Bank. GENISTEIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17727682.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoflavones; 6287WC5J2L / daidzein; 92M5F28TVF / glycitein; DH2M523P0H / Genistein
  •  go-up   go-down


39. Liu Z, Liu XL, Du QF, Xu N, Zhong M, Song LL, Yi ZS, Liu QF, Meng FY, Zhou SY: [Clinical characteristics and outcomes of 59 patients with acute lymphoblastic leukemia positive for BCR/ABL]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Mar;29(3):512-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and outcomes of 59 patients with acute lymphoblastic leukemia positive for BCR/ABL].
  • OBJECTIVE: To study the clinical characteristics and outcomes of BCR/ABL-positive acute lymphoblastic leukemia (BCR/ABL360888725-ALL) and screen the prognostic factors for BCR/ABL360888725-ALL.
  • The patients who failed to respond to the chemotherapy received subsequent consolidation chemotherapy with imatinib (400-800 mg/day) (17 cases) or allogeneic hematopoietic stem cell transplantation (allo-HSCT) (16 cases).
  • In patients with peripheral white blood cell (WBC) count <30=10(9)/L, 30-99.9(9)/L and > or =100(9)/L, the CR rates were 75.0% (18/24), 56.3% (9/15) and 26.3% (5/19) (P=0.006), and the overall survival probability of 2 years ( OSs of 2-yrs) was 24.7%, 22.5% and 21.1%, respectively (P=0.180).
  • According to the FAB classification, 56 cases were divided into L1, L2 and biphenotypic acute leukemia (BAL) subgroups, and their CR rates were 66.7% (6/9), 63.2% (24/38) and 22.2% (2/9) (P=0.029), with OSs of 2-yrs of 22.2%, 27.0% and 22.0%, respectively (P=0.623).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Genes, abl / genetics. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Benzamides. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19304540.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


40. Mayor NP, Shaw BE, Hughes DA, Maldonado-Torres H, Madrigal JA, Keshav S, Marsh SG: Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors. J Clin Oncol; 2007 Sep 20;25(27):4262-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors.
  • PURPOSE: Hematopoietic stem cell transplantation (HSCT) is an important option in the management of acute leukemia, but the risk of disease relapse and death remains appreciable.
  • PATIENTS AND METHODS: NOD2/CARD15 genotypes were analyzed in 196 patients diagnosed with acute leukemia and their unrelated donors.
  • T-cell depletion was used in 83% of pairs.
  • The incidence of acute graft-versus-host disease was low and there was no significant difference due to the presence of SNPs.
  • CONCLUSION: These data indicate an unrecognized role for the NOD2/CARD15 gene in unrelated donor HSCT for acute leukemia.
  • The increased risk of disease relapse suggests that the wild-type gene product may contribute to a graft-versus-leukemia effect.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / therapy. Nod2 Signaling Adaptor Protein / genetics. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cohort Studies. Female. HLA Antigens / metabolism. Hematopoietic Stem Cell Transplantation. Humans. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Recurrence

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Jan 10;26(2):338-9; author reply 339 [18182678.001]
  • (PMID = 17724347.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0200231
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / Immunosuppressive Agents; 0 / NOD2 protein, human; 0 / Nod2 Signaling Adaptor Protein
  •  go-up   go-down


41. Bain BJ, Fawcett N: A T-lineage neoplasm-Which one? Am J Hematol; 2009 Oct;84(10):678
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Biomarkers, Tumor / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. T-Lymphocytes / immunology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Antigens, CD / biosynthesis. Antigens, Neoplasm / analysis. Antigens, Neoplasm / biosynthesis. Diagnosis, Differential. Humans. Immunophenotyping. Leukemia, Prolymphocytic, T-Cell / diagnosis. Leukemia, Prolymphocytic, T-Cell / immunology. Leukemia, Prolymphocytic, T-Cell / pathology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19373891.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  •  go-up   go-down


42. Yamada T, Mishima K, Ota A, Moritani N, Matsumura T, Katase N, Yamamoto T: A case of ATLL (adult T-cell leukemia/lymphoma) mimicking odontogenic infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jun;109(6):e51-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ATLL (adult T-cell leukemia/lymphoma) mimicking odontogenic infection.
  • A case of adult T-cell leukemia/lymphoma (ATLL) in which cheek swelling was the initial symptom is presented.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / pathology. Maxilla / pathology. Periapical Abscess / pathology. Soft Tissue Infections / pathology. Tooth Diseases / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Humans. Male

  • MedlinePlus Health Information. consumer health - Tooth Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20451832.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Vega F, Padula A, Valbuena JR, Stancu M, Jones D, Medeiros LJ: Lymphomas involving the pleura: a clinicopathologic study of 34 cases diagnosed by pleural biopsy. Arch Pathol Lab Med; 2006 Oct;130(10):1497-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 29 (85.3%) cases, a specific diagnosis according to the World Health Organization classification could be made: 17 (58.6%) diffuse large B-cell lymphoma, 5 (17.2%) follicular lymphoma (including a case with areas of diffuse large B-cell lymphoma), 2 (6.9%) small lymphocytic lymphomas/chronic lymphocytic leukemia, 2 (6.9%) precursor T-cell lymphoblastic lymphoma/leukemia, 1 (3.4%) mantle cell lymphoma, 1 (3.4%) posttransplant lymphoproliferative disorder, and 1 (3.4%) classical Hodgkin lymphoma.
  • The other 5 cases were B-cell lymphomas that could not be further classified.
  • The most frequent type is diffuse large B-cell lymphoma, followed by follicular lymphoma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Body Fluids / cytology. Female. Humans. Immunophenotyping. Incidence. Lymphoma, B-Cell / epidemiology. Lymphoma, Follicular / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Male. Medical Records. Middle Aged. Neoplasms, Second Primary / pathology. Retrospective Studies. World Health Organization

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17090191.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Nadella MV, Dirksen WP, Nadella KS, Shu S, Cheng AS, Morgenstern JA, Richard V, Fernandez SA, Huang TH, Guttridge D, Rosol TJ: Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-kappaB in adult T-cell leukemia/lymphoma. Leukemia; 2007 Aug;21(8):1752-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-kappaB in adult T-cell leukemia/lymphoma.
  • Parathyroid hormone-related protein (PTHrP) plays a primary role in the development of humoral hypercalcemia of malignancy (HHM) that occurs in the majority of patients with adult T-cell leukemia/lymphoma (ATLL) due to human T-cell lymphotropic virus type-1 (HTLV-1) infection.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1997 Sep;71(9):6277-8 [9261343.001]
  • [Cites] J Biol Chem. 1997 Dec 26;272(52):33132-9 [9407099.001]
  • [Cites] Immunol Today. 1998 Feb;19(2):80-8 [9509763.001]
  • [Cites] Annu Rev Physiol. 1998;60:431-60 [9558472.001]
  • [Cites] J Bone Miner Res. 1999 Mar;14(3):406-14 [10027905.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2360-8 [10090947.001]
  • [Cites] Clin Chem. 2003 Aug;49(8):1398-402 [12881458.001]
  • [Cites] J Biol Chem. 1997 Feb 21;272(8):4953-8 [9030555.001]
  • [Cites] Virology. 1996 Dec 15;226(2):167-75 [8955035.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3744-50 [8670878.001]
  • [Cites] Blood. 1996 Aug 1;88(3):1035-45 [8704212.001]
  • [Cites] Mol Cell Biol. 1996 Apr;16(4):1342-8 [8657107.001]
  • [Cites] Endocrinology. 1996 Apr;137(4):1349-57 [8625910.001]
  • [Cites] Eur J Haematol. 1996 Jan-Feb;56(1-2):116-7 [8599987.001]
  • [Cites] Miner Electrolyte Metab. 1995;21(1-3):166-70 [7565442.001]
  • [Cites] J Biol Chem. 1995 Feb 17;270(7):3123-31 [7852394.001]
  • [Cites] Blood. 1993 Aug 1;82(3):722-31 [8338942.001]
  • [Cites] Genes Dev. 1993 Jul;7(7B):1354-63 [8330739.001]
  • [Cites] Mol Cell Biol. 1999 Aug;19(8):5785-99 [10409765.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1175-83 [15889157.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5952-64 [16155602.001]
  • [Cites] Mol Cell. 2006 Feb 3;21(3):393-404 [16455494.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5899-904 [16595631.001]
  • [Cites] Immunol Res. 2006;34(1):1-12 [16720895.001]
  • [Cites] J Virol. 1993 Jul;67(7):4205-13 [8510222.001]
  • [Cites] Mol Endocrinol. 1993 Feb;7(2):273-82 [8469240.001]
  • [Cites] Cell. 1993 Mar 12;72(5):729-39 [8453667.001]
  • [Cites] Curr Top Microbiol Immunol. 1992;182:421-4 [1490380.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Dec 15;189(2):938-43 [1472066.001]
  • [Cites] Mol Endocrinol. 1992 Oct;6(10):1642-52 [1280327.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):339-42 [1406939.001]
  • [Cites] Mol Endocrinol. 1990 Jun;4(6):851-8 [2233743.001]
  • [Cites] Gene. 1989 Apr 15;77(1):95-105 [2744490.001]
  • [Cites] Science. 1988 Sep 23;241(4873):1652-5 [2843985.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):556-63 [3043221.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Genes Dev. 2004 Sep 15;18(18):2195-224 [15371334.001]
  • [Cites] Cell. 2004 Aug 20;118(4):453-64 [15315758.001]
  • [Cites] Neoplasia. 2004 May-Jun;6(3):266-78 [15153339.001]
  • [Cites] EMBO J. 1997 Jun 16;16(12):3609-20 [9218802.001]
  • [Cites] J Neurochem. 2000 Oct;75(4):1377-89 [10987817.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6977-84 [11156399.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2219-28 [11395400.001]
  • [Cites] Rev Endocr Metab Disord. 2000 Nov;1(4):253-63 [11706739.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45380-6 [11567031.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1828-34 [12176906.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9722-32 [12509424.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2789-96 [12456498.001]
  • (PMID = 17554373.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA077911; United States / NCRR NIH HHS / RR / RR07073; United States / NCRR NIH HHS / RR / RR00168; United States / NCI NIH HHS / CA / CA100730; United States / NCRR NIH HHS / RR / T32 RR007073; United States / NCRR NIH HHS / RR / P51 RR000168; United States / NCRR NIH HHS / RR / K26 RR000168; United States / NCI NIH HHS / CA / CA77911; None / None / / P01 CA100730-01; United States / NCI NIH HHS / CA / P01 CA100730-01; United States / NCI NIH HHS / CA / P01 CA100730
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Parathyroid Hormone-Related Protein; 0 / RNA, Messenger; EC 2.3.1.28 / Chloramphenicol O-Acetyltransferase
  • [Other-IDs] NLM/ NIHMS94363; NLM/ PMC2676796
  •  go-up   go-down


45. Russell LJ, Akasaka T, Majid A, Sugimoto KJ, Loraine Karran E, Nagel I, Harder L, Claviez A, Gesk S, Moorman AV, Ross F, Mazzullo H, Strefford JC, Siebert R, Dyer MJ, Harrison CJ: t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood; 2008 Jan 01;111(1):387-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
  • Translocations involving the immunoglobulin heavy chain locus (IGH@) at chromosome band 14q32 are common in mature B-cell neoplasms, but are rare in B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
  • [MeSH-major] Immunoglobulin Heavy Chains / genetics. Inhibitor of Differentiation Proteins / genetics. Leukemia, B-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Base Sequence. Child. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 6. Chromosomes, Human, Pair 9. Female. Gene Deletion. Genes, p16. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Molecular Sequence Data. PAX5 Transcription Factor / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940204.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ID4 protein, human; 0 / Immunoglobulin Heavy Chains; 0 / Inhibitor of Differentiation Proteins; 0 / PAX5 Transcription Factor; 0 / PAX5 protein, human
  •  go-up   go-down


46. Mandac I, Kolonić SO, Vrhovac R, Lasan-Trcić R, Jakelić-Pitesa J, Kardum-Skelin I: T-lymphoblastic lymphoma with an unusual t(8;14)(q24;q11)--case report. Coll Antropol; 2010 Mar;34(1):265-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-lymphoblastic lymphoma with an unusual t(8;14)(q24;q11)--case report.
  • Cytogenetic abnormalities seen at presentation of acute lymphoblastic leukemia or lymphoblastic lymphoma (ALL/ LBL) are associated with distinct clinical and hematologic disease entities.
  • Flow cytometry of lymph node revealed T cell phenotype of immature cells: CD45+CD2+CD5+CD7+CD4+CD8+CD3cyt +CD3TdT+CD10-CD34-HLAD/DR-.
  • Southern blot analysis of extracted DNA from the supraclavicular lymph node demonstrated clonal rearrangement of the T cell antigen receptor (TCR/J) gene (region Vb+Jb2).
  • Based on these findings, diagnosis of T lymphoblastic non Hodgkin lymphoma was established.
  • [MeSH-major] Lymphoma, T-Cell / genetics. Lymphoma, T-Cell / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Translocation, Genetic
  • [MeSH-minor] Adult. Chromosome Aberrations. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 8. Fatal Outcome. Humans. In Situ Hybridization, Fluorescence. Lymph Nodes / pathology. Male. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432760.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


47. Chen W, Huang Q: Therapy-related acute lymphoblastic leukemia with t(8;14)(q11;32) but not 11q23 abnormality. Leuk Lymphoma; 2009 Feb;50(2):279-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute lymphoblastic leukemia with t(8;14)(q11;32) but not 11q23 abnormality.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 8 / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19197733.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


48. Nakazato T, Okudaira T, Ishikawa C, Nakama S, Sawada S, Tomita M, Uchihara JN, Taira N, Masuda M, Tanaka Y, Ohshiro K, Takasu N, Mori N: Anti-adult T-cell leukemia effects of a novel synthetic retinoid, Am80 (Tamibarotene). Cancer Sci; 2008 Nov;99(11):2286-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-adult T-cell leukemia effects of a novel synthetic retinoid, Am80 (Tamibarotene).
  • Clinical trials for treatment of adult T-cell leukemia (ATL) caused by human T-cell leukemia virus type I (HTLV-I) using all-trans-retinoic acid (ATRA) have shown satisfactory therapeutic responses, although efficacies were limited.
  • The present study examined the inhibitory effects of Am80 on HTLV-I-infected T-cell lines and ATL cells.
  • Am80 had negligible growth inhibition of peripheral blood mononuclear cells but marked growth inhibition of both HTLV-I-infected T-cell lines and ATL cells.
  • Am80 arrested cells in the G1 phase of the cell cycle and induced apoptosis in HTLV-I-infected T-cell lines.
  • It inhibited also the phosphorylation of IkappaBalpha and NF-kappaB-DNA binding, in conjunction with reduction of expression of proteins involved in the G1/S cell cycle transition and apoptosis.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Benzoates / pharmacology. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Tetrahydronaphthalenes / pharmacology
  • [MeSH-minor] Animals. Cell Cycle. Cell Division. Cell Line, Tumor. Female. Human T-lymphotropic virus 1 / pathogenicity. Humans. Mice. Mice, SCID

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Nakamura Y. Cancer Sci. 2011 Feb;102(2):499 [21265954.001]
  • (PMID = 18771528.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoates; 0 / Tetrahydronaphthalenes; 08V52GZ3H9 / tamibarotene
  •  go-up   go-down


49. Yaar R, Rothman K, Mahalingam M: When dead cells tell tales-cutaneous involvement by precursor T-cell acute lymphoblastic lymphoma with an uncommon phenotype. Am J Dermatopathol; 2010 Apr;32(2):183-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] When dead cells tell tales-cutaneous involvement by precursor T-cell acute lymphoblastic lymphoma with an uncommon phenotype.
  • The thymic type of precursor T-cell acute lymphoblastic lymphoma (pre-T ALL), an uncommon T-cell malignancy, typically presents as a thymic mass and expresses terminal deoxonucleotidyl transferase, CD7, and cytoplasmic CD3, with variable expression of other markers.
  • [MeSH-major] Phenotype. Precancerous Conditions / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Skin / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD3 / metabolism. Antigens, CD34 / metabolism. Antigens, CD7 / metabolism. Biopsy. Face. Humans. Male. Necrosis


50. Song JH, Schnittke N, Zaat A, Walsh CS, Miller CW: FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias. Leuk Res; 2008 Nov;32(11):1751-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias.
  • Engineered FBXW7 null cells display cell cycle and chromosome stability defects.
  • Mutations of FBXW7 have been found in human colorectal, ovarian, endometrial tumors and T-cell acute lymphocytic leukemias.
  • Prompted by these findings we have examined acute myeloid leukemia, non-Hodgkin's lymphoma, T-cell acute lymphocytic leukemia, B-cell acute lymphocytic leukemia and adult T-cell leukemia DNA for mutations of the FBXW7 gene.
  • As expected, mutations were found in T-cell acute lymphocytic leukemias.
  • However mutations of FBXW7 were also found in four of 118 B-cell acute lymphocytic leukemias and one of 24 adult T-cell leukemia samples.
  • These observations suggest that disruption of FBXW7 has a role in several forms of lymphocytic leukemias and not exclusively T-cell acute lymphocytic leukemia.
  • [MeSH-major] Burkitt Lymphoma / genetics. Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, Non-Hodgkin / genetics. Mutation / genetics. Ubiquitin-Protein Ligases / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18485478.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


51. Campana D: Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program; 2010;2010:7-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease in acute lymphoblastic leukemia.
  • In patients with acute lymphoblastic leukemia (ALL), treatment response is increasingly evaluated with minimal residual disease (MRD) assays.
  • ALL cells can be recognized by their clonal rearrangement of immunoglobulin and T-cell receptor genes, expression of gene fusions, and leukemia-associated immunophenotypes.
  • Assays based on polymerase chain reaction or flow cytometry can detect one ALL cell among 10,000 to 100,000 normal cells in clinical samples.
  • The vast majority of cases have antigen-receptor gene rearrangements and leukemia immunophenotypes for MRD monitoring; about half of the cases currently have suitable gene fusions.
  • The clinical significance of MRD has been conclusively demonstrated in both childhood and adult ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21239764.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA60419
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


52. Specchia G, Albano F, Anelli L, Zagaria A, Liso A, Pannunzio A, Archidiacono N, Liso V, Rocchi M: Molecular cytogenetic study of instability at 1q21 approximately q32 in adult acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2005 Jan 1;156(1):54-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular cytogenetic study of instability at 1q21 approximately q32 in adult acute lymphoblastic leukemia.
  • In the present paper, we report a molecular cytogenetic study of 1q abnormalities associated with t(8;14)(q24;q32) in an adult common B acute lymphoblastic leukemia case with FAB-L2 morphology.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 1. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15588856.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


53. Nakamura M, Hamasaki T, Tokitou M, Baba M, Hashimoto Y, Aoyama H: Discovery of tetrahydrotetramethylnaphthalene analogs as adult T-cell leukemia cell-selective proliferation inhibitors in a small chemical library constructed based on multi-template hypothesis. Bioorg Med Chem; 2009 Jul 1;17(13):4740-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery of tetrahydrotetramethylnaphthalene analogs as adult T-cell leukemia cell-selective proliferation inhibitors in a small chemical library constructed based on multi-template hypothesis.
  • Adult T cell leukemia (ATL), caused by infection of human T-lymphotropic virus type 1 (HTLV-1), has a poor prognosis and curative therapy is unavailable, so it is important to find or design superior lead compounds for the drug treatment of ATL.
  • We used our micro-reversed fragment-based drug design hypothesis and multi-template hypothesis to extract the tetrahydrotetramethylnaphthalene (TMN) skeleton from tamibarotene, a useful medicament for the treatment of acute promyelocytic leukemia (APL).
  • Structural development of TMN yielded highly ATL cell-selective growth inhibitors, including 2-acetyl-3-hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene (6).
  • Structure-activity relationship analysis suggests the existence of a specific target molecule for ATL cell-selective inhibition of proliferation through G2 arrest.
  • [MeSH-major] Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Tetrahydronaphthalenes / chemistry. Tetrahydronaphthalenes / pharmacology
  • [MeSH-minor] Apoptosis / drug effects. Cell Line, Tumor. Drug Design. Human T-lymphotropic virus 1 / isolation & purification. Humans. Models, Molecular. Molecular Structure. Retinoids. Small Molecule Libraries. Structure-Activity Relationship. T-Lymphocytes / cytology. T-Lymphocytes / virology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443225.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Retinoids; 0 / Small Molecule Libraries; 0 / Tetrahydronaphthalenes
  •  go-up   go-down


54. Goldstone AH, Rowe JM: Transplantation in adult ALL. Hematology Am Soc Hematol Educ Program; 2009;:593-601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplantation in adult ALL.
  • The value of the allogeneic graft-versus-leukemia effect in adult acute lymphoblastic leukemia (ALL) has now been conclusively demonstrated and confirmed.
  • Clinical indications to harness the allogeneic effect will mature as the true value of pediatric protocols in adult patients and the safety and efficacy of a sibling, unrelated and reduced intensity transplant emerge in this disease.

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20008244.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 44
  •  go-up   go-down


55. Kesic M, Doueiri R, Ward M, Semmes OJ, Green PL: Phosphorylation regulates human T-cell leukemia virus type 1 Rex function. Retrovirology; 2009 Nov 17;6:105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphorylation regulates human T-cell leukemia virus type 1 Rex function.
  • BACKGROUND: Human T-cell leukemia virus type 1 (HTLV-1) is a pathogenic complex deltaretrovirus, which is the causative agent of adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis.

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 1990 Jun 15;169(2):469-75 [2357216.001]
  • [Cites] Nature. 1989 Oct 5;341(6241):453-6 [2677743.001]
  • [Cites] J Virol. 1991 Jan;65(1):546-50 [1898667.001]
  • [Cites] J Virol. 1991 Jan;65(1):81-8 [1985219.001]
  • [Cites] Neurology. 1991 Jan;41(1):85-7 [1985300.001]
  • [Cites] J Virol. 1991 Jun;65(6):3379-83 [2033676.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5704-8 [1905815.001]
  • [Cites] J Virol. 1991 Aug;65(8):4408-13 [2072457.001]
  • [Cites] J Virol. 1991 Nov;65(11):6001-7 [1920623.001]
  • [Cites] Lancet. 1992 Mar 14;339(8794):645-6 [1347339.001]
  • [Cites] J Virol. 1992 Apr;66(4):2583-7 [1548784.001]
  • [Cites] J Virol. 1992 Jul;66(7):4325-30 [1602546.001]
  • [Cites] J Biol Chem. 1992 Oct 25;267(30):21977-81 [1400509.001]
  • [Cites] Virology. 1993 Mar;193(1):41-9 [8438577.001]
  • [Cites] Protein Sci. 1993 Mar;2(3):348-56 [8453373.001]
  • [Cites] J Virol. 1993 May;67(5):2496-502 [8474155.001]
  • [Cites] Ann Neurol. 1993 Apr;33(4):411-4 [8489213.001]
  • [Cites] J Virol. 1996 Sep;70(9):6442-5 [8709278.001]
  • [Cites] J Virol. 1996 Aug;70(8):5194-202 [8764028.001]
  • [Cites] J Virol. 1997 Feb;71(2):1181-90 [8995640.001]
  • [Cites] Blood Rev. 1997 Jun;11(2):91-104 [9242992.001]
  • [Cites] J Virol. 1997 Nov;71(11):8912-7 [9343258.001]
  • [Cites] J Virol. 1998 Jan;72(1):633-40 [9420268.001]
  • [Cites] J Virol. 1998 Aug;72(8):6602-7 [9658105.001]
  • [Cites] J Virol. 1998 Nov;72(11):8852-60 [9765430.001]
  • [Cites] Anal Chem. 1999 Jan 1;71(1):235-42 [9921130.001]
  • [Cites] J Virol. 1999 Jun;73(6):4856-65 [10233947.001]
  • [Cites] J Virol. 1999 Oct;73(10):8112-9 [10482560.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:620-42 [15569604.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:431-45 [15574380.001]
  • [Cites] Bioessays. 2005 Mar;27(3):285-98 [15714552.001]
  • [Cites] Mol Cell Proteomics. 2005 Mar;4(3):235-45 [15640519.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 31;102(22):7994-9 [15911757.001]
  • [Cites] Retrovirology. 2005;2:30 [15882466.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5931-7 [16155600.001]
  • [Cites] J Biol Chem. 2006 Oct 20;281(42):31705-12 [16923801.001]
  • [Cites] J Biol Chem. 2007 Aug 24;282(34):25088-99 [17597071.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Nov;8(11):904-16 [17878917.001]
  • [Cites] Retrovirology. 2008;5:76 [18702816.001]
  • [Cites] Retrovirology. 2008;5:92 [18922151.001]
  • [Cites] Retrovirology. 2009;6:9 [19187529.001]
  • [Cites] J Virol. 2009 May;83(10):5232-43 [19279097.001]
  • [Cites] J Virol. 2009 Sep;83(17):8859-68 [19553333.001]
  • [Cites] J Virol. 2000 Mar;74(6):2655-62 [10684280.001]
  • [Cites] N Engl J Med. 2000 Mar 30;342(13):930-6 [10738051.001]
  • [Cites] J Virol. 2001 Sep;75(18):8440-8 [11507189.001]
  • [Cites] Curr Opin Chem Biol. 2001 Oct;5(5):591-602 [11578935.001]
  • [Cites] J Virol. 2003 Jul;77(14):7728-35 [12829812.001]
  • [Cites] J Biomol Tech. 2003 Sep;14(3):205-15 [13678151.001]
  • [Cites] Prog Cell Cycle Res. 2003;5:477-87 [14593743.001]
  • [Cites] J Virol. 2003 Dec;77(23):12829-40 [14610204.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3963-9 [12907436.001]
  • [Cites] Science. 1985 Aug 16;229(4714):675-9 [2992082.001]
  • [Cites] Nature. 1985 Dec 12-18;318(6046):571-4 [2999613.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jun;84(11):3653-7 [3035544.001]
  • [Cites] Blood. 1988 Feb;71(2):363-9 [2827811.001]
  • [Cites] Cell. 1988 Oct 21;55(2):197-209 [3048703.001]
  • [Cites] Cell. 1989 Jul 14;58(1):205-14 [2752419.001]
  • [Cites] Virology. 1990 Sep;178(1):327-30 [2202148.001]
  • (PMID = 19919707.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA076595; United States / NCI NIH HHS / CA / CA100730
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gene Products, rex; 0 / rex Protein, Human T-lymphotropic virus 1; 1114-81-4 / Phosphothreonine; 17885-08-4 / Phosphoserine
  • [Other-IDs] NLM/ PMC2780990
  •  go-up   go-down


56. Suzumiya J, Ohshima K, Tamura K, Karube K, Uike N, Tobinai K, Gascoyne RD, Vose JM, Armitage JO, Weisenburger DD, International Peripheral T-Cell Lymphoma Project: The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project. Ann Oncol; 2009 Apr;20(4):715-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project.
  • BACKGROUND: The International Peripheral T-cell Lymphoma Project was organized to better understand the T-cell and natural killer (NK) cell lymphomas, and our task is to present the clinicopathologic correlations and therapeutic results for adult T-cell leukemia/lymphoma (ATL).
  • PATIENTS AND METHODS: Among 1153 patients with T-cell or NK cell lymphomas, 126 patients (9.6%) with ATL were represented in this project.
  • All were categorized as aggressive ATL, i.e. acute or lymphoma type, and 87% fell into the lymphoma type.

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19150954.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Investigator] Savage K; Connors J; Gascoyne R; Chhanabhai M; Wilson W; Jaffe E; Armitage J; Vose J; Weisenburger D; Anderson J; Ullrich F; Bast M; Hochberg E; Harris N; Levine A; Nathwani B; Miller T; Rimsza L; Montserrat E; Lopez-Guillermo A; Campo E; Cuadros M; Alvarez Ferreira J; Martinez Delgado B; Holte H; Delabie J; Rüdiger T; Müller-Hermelink K; Reimer P; Adam P; Wilhelm M; Schmitz N; Nerl C; MacLennan KA; Zinzani PL; Pileri S; Federico M; Bellei M; Coiffier B; Berger F; Tanin I; Wannakrairot P; Au W; Liang R; Loong F; Rajan S; Sng I; Tobinai K; Matsuno Y; Morishima Y; Nakamura S; Seto M; Tanimoto M; Yoshino T; Suzumiya J; Ohshima K; Kim WS; Ko YH
  •  go-up   go-down


57. Haider S, Hayakawa K, Itoyama T, Sadamori N, Kurosawa N, Isobe M: TCR variable gene involvement in chromosome inversion between 14q11 and 14q24 in adult T-cell leukemia. J Hum Genet; 2006;51(4):326-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TCR variable gene involvement in chromosome inversion between 14q11 and 14q24 in adult T-cell leukemia.
  • Chromosomal translocations in T-cell malignancies frequently involve the T-cell receptor (TCR)alpha/delta locus at chromosome 14q11.
  • Although 14q11 abnormalities are found in about 10% of adult T-cell leukemia (ATL) cases, until now there has been no direct evidence showing involvement of the TCR locus in ATL-a malignancy closely associated with HTLV-1 infection.
  • The breakpoints of T-cell malignancies most commonly occur within the Jalpha or Jdelta region of the TCR locus.
  • [MeSH-major] Chromosome Inversion. Chromosomes, Human, Pair 14. Gene Expression Regulation, Leukemic. Genes, T-Cell Receptor. Leukemia-Lymphoma, Adult T-Cell / genetics
  • [MeSH-minor] ADAM Proteins / metabolism. Adult. Animals. Base Sequence. Blotting, Southern. COS Cells. Cells, Cultured. Cercopithecus aethiops. DNA / genetics. Electrophoresis, Polyacrylamide Gel. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Leukocytes, Mononuclear / cytology. Membrane Proteins / metabolism. Models, Genetic. Molecular Sequence Data. Restriction Mapping. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA. Transfection

  • Nature Publishing Group. Nature Publishing Group (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520872.001).
  • [ISSN] 1434-5161
  • [Journal-full-title] Journal of human genetics
  • [ISO-abbreviation] J. Hum. Genet.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ DQ202398/ DQ302756
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Membrane Proteins; 9007-49-2 / DNA; EC 3.4.24.- / ADAM 12 protein; EC 3.4.24.- / ADAM Proteins
  •  go-up   go-down


58. Okajima M, Takahashi M, Higuchi M, Ohsawa T, Yoshida S, Yoshida Y, Oie M, Tanaka Y, Gejyo F, Fujii M: Human T-cell leukemia virus type 1 Tax induces an aberrant clustering of the tumor suppressor Scribble through the PDZ domain-binding motif dependent and independent interaction. Virus Genes; 2008 Oct;37(2):231-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human T-cell leukemia virus type 1 Tax induces an aberrant clustering of the tumor suppressor Scribble through the PDZ domain-binding motif dependent and independent interaction.
  • Human T-cell leukemia virus type 1 (HTLV-1) is a causative agent of adult T-cell leukemia.
  • Endogenous Scribble was diffusely localized at the plasma membrane of HTLV-1-uninfected T-cell lines, whereas it colocalized with Tax1 as small and large aggregate at the plasma membranes.
  • [MeSH-minor] Binding Sites. Cell Line. Cell Membrane / genetics. Cell Membrane / metabolism. Humans. Jurkat Cells. PDZ Domains. Protein Binding. Protein Transport

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virology. 2003 Feb 1;306(1):60-7 [12620798.001]
  • [Cites] Int Rev Cytol. 2007;262:253-302 [17631191.001]
  • [Cites] Int J Cancer. 1991 Jun 19;48(4):623-30 [1710610.001]
  • [Cites] Retrovirology. 2006 Oct 17;3:71 [17042961.001]
  • [Cites] Blood. 2016 Dec 15;128(24):2745 [27979862.001]
  • [Cites] J Biol Chem. 2007 Nov 9;282(45):33132-41 [17855372.001]
  • [Cites] Oncogene. 1998 Feb 5;16(5):643-54 [9482110.001]
  • [Cites] Hum Mol Genet. 2003 Jan 15;12(2):87-98 [12499390.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5965-75 [16155603.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] J Virol. 2002 Mar;76(6):2648-53 [11861831.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1980-8 [16263794.001]
  • [Cites] J Virol. 1999 Feb;73(2):1271-7 [9882331.001]
  • [Cites] Nat Cell Biol. 2003 Feb;5(2):166-70 [12545176.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6670-5 [9192623.001]
  • [Cites] Int J Cancer. 1984 Aug 15;34(2):221-8 [6088403.001]
  • [Cites] Oncogene. 1999 Sep 30;18(40):5487-96 [10523825.001]
  • [Cites] Immunity. 2005 Jun;22(6):737-48 [15963788.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5996-6004 [16155606.001]
  • [Cites] Virology. 2004 Jan 5;318(1):327-36 [14972558.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11612-6 [9326658.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] Virology. 2004 Mar 1;320(1):52-62 [15003862.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Retrovirology. 2005 Jul 23;2:46 [16042787.001]
  • [Cites] J Virol. 2007 Nov;81(21):11900-7 [17715223.001]
  • [Cites] Mol Cell Biol. 2000 Nov;20(21):8244-53 [11027293.001]
  • [Cites] Oncogene. 1991 Dec;6(12):2349-52 [1766679.001]
  • [Cites] Oncogene. 1999 Oct 28;18(44):5967-72 [10557085.001]
  • [Cites] Science. 2000 Jul 7;289(5476):113-6 [10884224.001]
  • [Cites] J Biol Chem. 2004 Oct 8;279(41):43307-20 [15269214.001]
  • (PMID = 18661220.001).
  • [ISSN] 0920-8569
  • [Journal-full-title] Virus genes
  • [ISO-abbreviation] Virus Genes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / Membrane Proteins; 0 / SCRIB protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


59. Tomita M, Kawakami H, Uchihara JN, Okudaira T, Masuda M, Matsuda T, Tanaka Y, Ohshiro K, Mori N: Inhibition of constitutively active Jak-Stat pathway suppresses cell growth of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. Retrovirology; 2006;3:22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of constitutively active Jak-Stat pathway suppresses cell growth of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells.
  • BACKGROUND: Human T-cell leukemia virus type 1 (HTLV-1), the etiologic agent for adult T-cell leukemia (ATL), induces cytokine-independent proliferation of T-cells, associated with the acquisition of constitutive activation of Janus kinases (Jak) and signal transducers and activators of transcription (Stat) proteins.
  • RESULTS: Constitutive activation of Stat3 and Stat5 was observed in HTLV-1-infected T-cell lines and primary ATL cells, but not in HTLV-1-negative T-cell lines.
  • AG490 inhibited the growth of HTLV-1-infected T-cell lines and primary ATL cells by inducing G1 cell-cycle arrest mediated by altering the expression of cyclin D2, Cdk4, p53, p21, Pim-1 and c-Myc, and by apoptosis mediated by the reduced expression of c-IAP2, XIAP, survivin and Bcl-2.
  • [MeSH-minor] Base Sequence. Cell Line. Cell Line, Tumor. DNA Primers. Enzyme Inhibitors / pharmacology. Humans. Leukemia-Lymphoma, Adult T-Cell. Phosphorylation. Protein-Tyrosine Kinases / metabolism. STAT Transcription Factors / metabolism. Signal Transduction. Tyrphostins / pharmacology

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2002 Sep;76(18):9389-97 [12186921.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1828-34 [12176906.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1535-42 [12393476.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8523-30 [14679020.001]
  • [Cites] Oncogene. 2004 Oct 28;23(50):8272-81 [15467747.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Nature. 1981 Dec 24;294(5843):770-1 [6275274.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] J Exp Med. 1985 Dec 1;162(6):2169-74 [2866223.001]
  • [Cites] Int J Cancer. 1986 Jan 15;37(1):35-42 [3000953.001]
  • [Cites] J Virol. 1989 Aug;63(8):3220-6 [2501514.001]
  • [Cites] Int J Cancer. 1990 Feb 15;45(2):237-43 [2303290.001]
  • [Cites] Jpn J Cancer Res. 1990 Mar;81(3):225-31 [2161813.001]
  • [Cites] Int J Cancer. 1990 Oct 15;46(4):675-81 [1698731.001]
  • [Cites] Science. 1995 Jul 7;269(5220):79-81 [7604283.001]
  • [Cites] Annu Rev Biochem. 1995;64:621-51 [7574495.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3619-39 [7579327.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3410-7 [8605359.001]
  • [Cites] Nature. 1996 Feb 15;379(6566):645-8 [8628398.001]
  • [Cites] Nature. 1996 Aug 8;382(6591):511-7 [8700224.001]
  • [Cites] Biol Pharm Bull. 1996 Nov;19(11):1518-20 [8951178.001]
  • [Cites] Science. 1997 Sep 12;277(5332):1630-5 [9287210.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13897-902 [9391124.001]
  • [Cites] J Virol. 1998 May;72(5):4408-12 [9557732.001]
  • [Cites] J Exp Med. 1999 Jan 4;189(1):63-73 [9874564.001]
  • [Cites] J Immunol. 1999 Jan 15;162(2):1144-9 [9916745.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2360-8 [10090947.001]
  • [Cites] J Immunol. 1999 Apr 1;162(7):3897-904 [10201908.001]
  • [Cites] Oncogene. 1999 Apr 29;18(17):2667-75 [10348340.001]
  • [Cites] Int J Cancer. 2005 Jul 20;115(6):967-74 [15729715.001]
  • [Cites] Retrovirology. 2005;2:27 [15854229.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):765-72 [16106398.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S11-8 [12528768.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3847-54 [10572100.001]
  • [Cites] Endocrinology. 1999 Dec;140(12):5659-68 [10579330.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3915-21 [10845928.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2474-88 [10851046.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2496-504 [10851048.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2511-22 [10851050.001]
  • [Cites] Br J Haematol. 2000 Jun;109(4):823-8 [10929036.001]
  • [Cites] J Immunol. 2000 Nov 1;165(9):5097-104 [11046040.001]
  • [Cites] Oncogene. 2001 Mar 1;20(9):1094-102 [11314046.001]
  • [Cites] Oncogene. 2001 Apr 19;20(17):2055-67 [11360190.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Blood. 2001 Aug 1;98(3):823-9 [11468184.001]
  • [Cites] J Immunol. 2002 Feb 15;168(4):1524-7 [11823475.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):378-85 [11992406.001]
  • [RetractionIn] Tomita M, Kawakami H, Uchihara JN, Okudaira T, Masuda M, Matsuda T, Tanaka Y, Ohshiro K, Mori N. Retrovirology. 2011;8:1 [21210996.001]
  • (PMID = 16603085.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Enzyme Inhibitors; 0 / STAT Transcription Factors; 0 / STAT3 Transcription Factor; 0 / STAT5 Transcription Factor; 0 / Tyrphostins; 0 / alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Other-IDs] NLM/ PMC1483830
  •  go-up   go-down


60. Harashima N, Tanosaki R, Shimizu Y, Kurihara K, Masuda T, Okamura J, Kannagi M: Identification of two new HLA-A*1101-restricted tax epitopes recognized by cytotoxic T lymphocytes in an adult T-cell leukemia patient after hematopoietic stem cell transplantation. J Virol; 2005 Aug;79(15):10088-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of two new HLA-A*1101-restricted tax epitopes recognized by cytotoxic T lymphocytes in an adult T-cell leukemia patient after hematopoietic stem cell transplantation.
  • We previously reported that Tax-specific CD8(+) cytotoxic T lymphocytes (CTLs), directed to single epitopes restricted by HLA-A2 or A24, expanded in vitro and in vivo in peripheral blood mononuclear cells (PBMC) from some adult T-cell leukemia (ATL) patients after but not before allogeneic hematopoietic stem cell transplantation (HSCT).
  • [MeSH-major] Epitopes / immunology. Gene Products, tax / immunology. HLA-A Antigens / immunology. Leukemia-Lymphoma, Adult T-Cell / immunology. Leukemia-Lymphoma, Adult T-Cell / therapy. Stem Cell Transplantation. T-Lymphocytes, Cytotoxic / immunology
  • [MeSH-minor] Amino Acid Sequence. Coculture Techniques. Human T-lymphotropic virus 1 / immunology. Humans. Leukocytes, Mononuclear. Male. Middle Aged. Molecular Sequence Data. Peptides / genetics. T-Cell Antigen Receptor Specificity. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunogenetics. 1999 Nov;50(3-4):201-12 [10602880.001]
  • [Cites] Immunol Today. 1996 Jun;17(6):261-6 [8962628.001]
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):15-20 [11244433.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 5;93(23):1775-83 [11734593.001]
  • [Cites] Br J Haematol. 2003 Jan;120(2):304-9 [12542491.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):391-9 [14729650.001]
  • [Cites] Trends Microbiol. 2004 Jul;12(7):346-52 [15223062.001]
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] J Immunol. 1980 Mar;124(3):1045-9 [6244347.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] J Immunol. 1999 Feb 1;162(3):1765-71 [9973440.001]
  • [Cites] J Immunol. 1999 Nov 1;163(9):4994-5004 [10528204.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):128-41 [2891797.001]
  • [Cites] Nature. 1990 Nov 15;348(6298):245-8 [2146511.001]
  • [Cites] Int Immunol. 1991 Aug;3(8):761-7 [1911545.001]
  • [Cites] J Virol. 1992 May;66(5):2928-33 [1373197.001]
  • [Cites] Virology. 1992 Jun;188(2):628-36 [1374983.001]
  • [Cites] J Immunol. 1992 Jul 1;149(1):214-21 [1607654.001]
  • [Cites] J Exp Med. 1993 Jun 1;177(6):1567-73 [8496677.001]
  • [Cites] J Immunol. 1993 Oct 1;151(7):3874-83 [7690819.001]
  • [Cites] J Immunol. 1994 Jan 1;152(1):163-75 [8254189.001]
  • [Cites] J Immunol. 1994 Apr 15;152(8):3913-24 [8144960.001]
  • [Cites] N Engl J Med. 1996 Feb 1;334(5):281-5 [8532022.001]
  • [Cites] J Virol. 2000 Oct;74(20):9610-6 [11000233.001]
  • (PMID = 16014972.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epitopes; 0 / Gene Products, tax; 0 / HLA-A Antigens; 0 / Peptides
  • [Other-IDs] NLM/ PMC1181560
  •  go-up   go-down


61. Kühnl A, Gökbuget N, Stroux A, Burmeister T, Neumann M, Heesch S, Haferlach T, Hoelzer D, Hofmann WK, Thiel E, Baldus CD: High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. Blood; 2010 May 6;115(18):3737-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia.
  • Overexpression of BAALC is an adverse prognostic factor in adults with cytogenetically normal acute myeloid leukemia and T-cell acute lymphoblastic leukemia (ALL).
  • Here, we analyzed the prognostic significance of BAALC in B-precursor ALL.
  • BAALC MRNA expression was determined in 368 primary adult B-precursor ALL patients enrolled on the 06/99 and 07/03 GMALL trials.
  • Higher BAALC expression (T3 vs T2 vs T1) was associated with higher age (P < .001), a higher white blood cell count (P = .008), CD34 (P = .001), BCR-ABL (P < .001), and MLL-AF4 (P < .001).
  • Gene-expression profiling revealed an up-regulation of stem cell markers and genes involved in chemoresistance (TSPAN7 and LYN) in the high BAALC group.
  • Determination of BAALC might contribute to risk assessment of molecularly undefined adult B-precursor ALL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / metabolism. Drug Resistance, Neoplasm. Neoplasm Proteins / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Gene Expression Profiling. Humans. Immunophenotyping. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Oncogene Proteins, Fusion / genetics. Oncogene Proteins, Fusion / metabolism. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2010 May 6;115(18):3649-50 [20448115.001]
  • (PMID = 20065290.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BAALC protein, human; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


62. Delebecque F, Combredet C, Gabet AS, Wattel E, Brahic M, Tangy F: A chimeric human T cell leukemia virus type I bearing a deltaR Moloney-murine leukemia virus envelope infects mice persistently and induces humoral and cellular immune responses. J Infect Dis; 2005 Jan 15;191(2):255-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A chimeric human T cell leukemia virus type I bearing a deltaR Moloney-murine leukemia virus envelope infects mice persistently and induces humoral and cellular immune responses.
  • Human T cell lymphotropic virus (HTLV) type I is the agent of adult T cell leukemia and HTLV-I-associated myelopathy.
  • We report the infection of adult BALB/c, C3H/He, 129Sv, and 129Sv IFNAR(-/-) mice with an infectious chimeric HTLV-I provirus bearing the Moloney-murine leukemia virus (Mo-MuLV) envelope glycoprotein truncated for the C-terminal R peptide.
  • [MeSH-major] Chimera / immunology. Human T-lymphotropic virus 1 / immunology. Moloney murine leukemia virus / immunology. Viral Envelope Proteins / immunology
  • [MeSH-minor] Animals. Antibody Formation / immunology. Cell Line. Disease Models, Animal. Humans. Immunity, Cellular / immunology. Mice. Proviruses

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15609236.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Viral Envelope Proteins
  •  go-up   go-down


63. Koga Y, Iwanaga M, Soda M, Inokuchi N, Sasaki D, Hasegawa H, Yanagihara K, Yamaguchi K, Kamihira S, Yamada Y: Trends in HTLV-1 prevalence and incidence of adult T-cell leukemia/lymphoma in Nagasaki, Japan. J Med Virol; 2010 Apr;82(4):668-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in HTLV-1 prevalence and incidence of adult T-cell leukemia/lymphoma in Nagasaki, Japan.
  • Most previous studies aimed at estimating the number of human T-cell leukemia virus type-1 (HTLV-1) carriers in endemic areas have been based on seroprevalence rates in blood donors; however, this may result in underestimation because of the healthy donor effect.
  • The incidence of adult T-cell leukemia/lymphoma (ATLL) among HTLV-1 carriers was estimated using data from the Nagasaki Prefectural Cancer Registry.
  • [MeSH-major] HTLV-I Infections / complications. HTLV-I Infections / epidemiology. Human T-lymphotropic virus 1 / isolation & purification. Leukemia-Lymphoma, Adult T-Cell / epidemiology. Leukemia-Lymphoma, Adult T-Cell / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carrier State / epidemiology. Child. Child, Preschool. Female. Hospitals. Humans. Incidence. Infant. Infant, Newborn. Japan. Male. Middle Aged. Seroepidemiologic Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20166187.001).
  • [ISSN] 1096-9071
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


64. Ohyashiki JH, Hamamura R, Kobayashi C, Zhang Y, Ohyashiki K: A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells. Adv Appl Bioinform Chem; 2008;1:85-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells.
  • A proteasome inhibitor, bortezomib, could be a potential therapeutic agent in treating adult T-cell leukemia (ATL) patients, however, the underlying mechanism by which bortezomib induces cell death in ATL cells via gene regulatory network has not been fully elucidated.
  • Here we show that a Bayesian statistical framework by VoyaGene(®) identified a secreted protein acidic and rich in cysteine (SPARC) gene, a tumor-invasiveness related gene, as a possible modulator of bortezomib-induced cell death in ATL cells.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Matrix Biol. 2001 Jan;19(8):816-27 [11223341.001]
  • [Cites] Leuk Lymphoma. 1997 Jul;26(3-4):327-35 [9322895.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9 [12391322.001]
  • [Cites] Br J Haematol. 2003 Sep;122(5):728-44 [12930383.001]
  • [Cites] J Dermatol. 2003 Sep;30(9):641-3 [14578552.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2039-46 [15026341.001]
  • [Cites] Nat Biotechnol. 2005 Feb;23(2):238-43 [15654329.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):630-9 [15659509.001]
  • [Cites] Nat Genet. 2005 Mar;37(3):243-53 [15711544.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4051-8 [15899794.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4467-70 [15930259.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):310-6 [16052522.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):599-608 [16449999.001]
  • [Cites] Br J Cancer. 2007 Oct 22;97(8):1099-105 [17895889.001]
  • [Cites] Leukemia. 1998 Jun;12(6):1001 [9639435.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1357-63 [15190257.001]
  • [Cites] J Bioinform Comput Biol. 2004 Sep;2(3):533-50 [15359425.001]
  • [Cites] Oncogene. 2005 Jan 13;24(3):419-30 [15543232.001]
  • [Cites] Int J Mol Med. 2005 Aug;16(2):263-8 [16012759.001]
  • [Cites] Bioinformatics. 2006 Apr 1;22(7):815-22 [16418235.001]
  • [Cites] Leukemia. 2006 Aug;20(8):1341-52 [16810203.001]
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):319-25 [17235047.001]
  • [Cites] Oncogene. 2007 Dec 13;26(57):7859-71 [17603561.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3448-52 [8159767.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Sep 21;287(2):422-6 [11554745.001]
  • (PMID = 21918608.001).
  • [ISSN] 1178-6949
  • [Journal-full-title] Advances and applications in bioinformatics and chemistry : AABC
  • [ISO-abbreviation] Adv Appl Bioinform Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3169936
  • [Keywords] NOTNLM ; SPARC / adult T cell leukemia / bortezomib / network biology
  •  go-up   go-down


65. Ching YP, Chan SF, Jeang KT, Jin DY: The retroviral oncoprotein Tax targets the coiled-coil centrosomal protein TAX1BP2 to induce centrosome overduplication. Nat Cell Biol; 2006 Jul;8(7):717-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-cell leukaemia virus type I (HTLV-I) is etiologically associated with adult T-cell leukaemia (ATL).
  • [MeSH-major] Cell Transformation, Neoplastic / metabolism. Centrosome / metabolism. Gene Products, tax / metabolism. Human T-lymphotropic virus 1 / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Leukemia-Lymphoma, Adult T-Cell / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16767081.001).
  • [ISSN] 1465-7392
  • [Journal-full-title] Nature cell biology
  • [ISO-abbreviation] Nat. Cell Biol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ DQ139275
  • [Grant] United States / FIC NIH HHS / TW / R01 TW06186-01; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / RNA, Small Interfering; 0 / VAC14 protein, human
  •  go-up   go-down


66. Washiyama M, Nishigaki K, Ahmed N, Kinpara S, Ishii Y, Kanzawa N, Masuda T, Kannagi M: IL-2 withdrawal induces HTLV-1 expression through p38 activation in ATL cell lines. FEBS Lett; 2007 Nov 13;581(27):5207-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IL-2 withdrawal induces HTLV-1 expression through p38 activation in ATL cell lines.
  • Expression of human T-cell leukemia virus type-1 (HTLV-1) in adult T-cell leukemia (ATL) cells is known to be marginal in vivo and inducible in short-term culture.
  • In this study, we demonstrated that withdrawal of interleukin (IL)-2 from IL-2-dependent ATL cell lines resulted in induction of HTLV-1 mRNA and protein expression, and that viral induction was associated with phosphorylation of the stress kinase p38 and its downstream CREB.
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. Cyclic AMP Response Element-Binding Protein / metabolism. DNA Primers / genetics. DNA, Viral / genetics. Gene Expression Regulation, Viral / drug effects. Genes, Viral / drug effects. Genes, gag. HTLV-I Antigens / biosynthesis. HTLV-I Antigens / genetics. Humans. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / virology. MAP Kinase Signaling System / drug effects. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Viral / genetics. RNA, Viral / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950728.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CREB1 protein, human; 0 / Cyclic AMP Response Element-Binding Protein; 0 / DNA Primers; 0 / DNA, Viral; 0 / HTLV-I Antigens; 0 / Interleukin-2; 0 / RNA, Messenger; 0 / RNA, Viral; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


67. Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, Ferrando A, Fielding AK, Goldstone AH, Ketterling RP, Litzow MR, Luger SM, McMillan AK, Mansour MR, Rowe JM, Tallman MS, Lazarus HM: T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood; 2009 Dec 10;114(25):5136-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).
  • The biology and outcome of adult T-cell acute lymphoblastic leukemia are poorly understood.
  • This study provides a baseline for trials of new drugs, such as nelarabine, and may allow risk-adapted therapy in patients with poor-prognosis T-cell ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation / methods. T-Lymphocytes / pathology
  • [MeSH-minor] Adult. Cytogenetic Analysis. Female. Fusion Proteins, bcr-abl / genetics. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prospective Studies. Remission Induction. Survival Analysis. Transplantation, Homologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol Methods. 2000 Sep 21;243(1-2):59-75 [10986407.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4352-6 [19635999.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Apr;16(2):245-99, v [12094473.001]
  • [Cites] Arch Pathol Lab Med. 2003 Jan;127(1):42-8 [12521365.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Dec;16(4):671-83 [14592650.001]
  • [Cites] Lancet. 2004 Feb 14;363(9408):535-6 [14975618.001]
  • [Cites] Blood. 2004 Jul 15;104(2):558-60 [15044257.001]
  • [Cites] Blut. 1990 Jan;60(1):48-51 [2297585.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Mar;52(1):79-84 [2009514.001]
  • [Cites] Leukemia. 1996 Nov;10(11):1832-3 [8892689.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3931-9 [10339502.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3028-37 [15256423.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Blood. 2006 Jan 15;107(2):473-9 [16179376.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(11):989-95 [16633362.001]
  • [Cites] Blood. 2006 Jul 15;108(2):465-72 [16556888.001]
  • [Cites] Blood. 2007 Feb 1;109(3):910-5 [17023577.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Leukemia. 2007 Apr;21(4):604-11 [17287850.001]
  • [Cites] Leukemia. 2007 Apr;21(4):622-6 [17301806.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3739-45 [17646667.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Nature. 2008 Apr 10;452(7188):764-7 [18401411.001]
  • [Cites] Br J Haematol. 2008 Oct;143(2):153-68 [18691165.001]
  • [Cites] Blood. 2009 Jan 1;113(1):100-7 [18838613.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3918-24 [19109228.001]
  • [Cites] Haematologica. 2001 Jul;86(7):675-92 [11454522.001]
  • (PMID = 19828704.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U137686856; United Kingdom / Medical Research Council / / G8223452; United Kingdom / Medical Research Council / / G0500389; United States / NCI NIH HHS / CA / R01CA120196; United States / NCI NIH HHS / CA / R01 CA120196; United States / NCI NIH HHS / CA / U24 CA114737; United States / NCI NIH HHS / CA / R01 CA120196-03
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Other-IDs] NLM/ PMC2792210
  •  go-up   go-down


68. Jain P, Mostoller K, Flaig KE, Ahuja J, Lepoutre V, Alefantis T, Khan ZK, Wigdahl B: Identification of human T cell leukemia virus type 1 tax amino acid signals and cellular factors involved in secretion of the viral oncoprotein. J Biol Chem; 2007 Nov 23;282(47):34581-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of human T cell leukemia virus type 1 tax amino acid signals and cellular factors involved in secretion of the viral oncoprotein.
  • Human T cell leukemia virus type 1 (HTLV-1) is the etiologic agent of a number of pathologic abnormalities, including adult T cell leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
  • Recently, cell-free Tax was detected in the cerebrospinal fluid of HAM/TSP patients, implying that extracellular Tax may be relevant to neurologic disease.
  • Tax was shown to interact with a number of cellular secretory pathway proteins in both the model cell line BHK (baby hamster kidney)-21 and an HTLV-1-infected T cell line, C8166, physiologically relevant to HTLV-1-induced disease.
  • [MeSH-minor] Animals. Cricetinae. Gene Silencing. Humans. Jurkat Cells. Leukemia-Lymphoma, Adult T-Cell / cerebrospinal fluid. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / virology. Paraparesis, Tropical Spastic / cerebrospinal fluid. Paraparesis, Tropical Spastic / genetics. Paraparesis, Tropical Spastic / virology. Protein Structure, Tertiary / physiology. Protein Transport / physiology

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17897946.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2R01 CA 054559-13A1; United States / NINDS NIH HHS / NS / NS 044801
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / Nuclear Export Signals
  •  go-up   go-down


69. Utsunomya A: [Clinical and hematological characteristics of adult T-cell leukemia/lymphoma]. Rinsho Ketsueki; 2006 Dec;47(12):1502-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and hematological characteristics of adult T-cell leukemia/lymphoma].
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell
  • [MeSH-minor] Benzamides / therapeutic use. Boronic Acids / therapeutic use. Bortezomib. Carrier State / epidemiology. Carrier State / transmission. Cyclohexanones / therapeutic use. HIV Protease Inhibitors / therapeutic use. Human T-lymphotropic virus 1. Humans. Infectious Disease Transmission, Vertical. NF-kappa B / antagonists & inhibitors. Protease Inhibitors / therapeutic use. Pyrazines / therapeutic use. Ritonavir / therapeutic use. Stem Cell Transplantation. Transplantation, Homologous

  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17233468.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Benzamides; 0 / Boronic Acids; 0 / Cyclohexanones; 0 / HIV Protease Inhibitors; 0 / NF-kappa B; 0 / Protease Inhibitors; 0 / Pyrazines; 0 / dehydroxymethylepoxyquinomicin; 69G8BD63PP / Bortezomib; O3J8G9O825 / Ritonavir
  • [Number-of-references] 91
  •  go-up   go-down


70. Hiraragi H, Michael B, Nair A, Silic-Benussi M, Ciminale V, Lairmore M: Human T-lymphotropic virus type 1 mitochondrion-localizing protein p13II sensitizes Jurkat T cells to Ras-mediated apoptosis. J Virol; 2005 Aug;79(15):9449-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-lymphotropic virus type 1 (HTLV-1) is the etiological agent of adult T-cell leukemia.
  • We have demonstrated that proviral clones of HTLV-1 which are mutated in pX ORF II fail to obtain typical proviral loads and antibody responses in a rabbit animal model. p13(II) localizes to mitochondria and reduces cell growth and tumorigenicity in mice, but its function in human lymphocytes remains undetermined.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virology. 1997 Oct 13;237(1):123-8 [9344914.001]
  • [Cites] J Virol. 1997 Jan;71(1):75-83 [8985325.001]
  • [Cites] J Virol. 1998 Mar;72(3):2554-9 [9499124.001]
  • [Cites] J Virol. 1998 May;72(5):4458-62 [9557741.001]
  • [Cites] Oncogene. 1999 Aug 5;18(31):4505-14 [10442641.001]
  • [Cites] J Virol. 2000 Feb;74(3):1094-100 [10627519.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):567-72 [10662802.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1765-70 [11080824.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1771-6 [11080825.001]
  • [Cites] J Virol. 2000 Dec;74(24):11988-92 [11090202.001]
  • [Cites] Anticancer Drugs. 2001 Mar;12(3):163-84 [11290863.001]
  • [Cites] Methods Enzymol. 2001;333:73-87 [11400356.001]
  • [Cites] Leukemia. 2001 Aug;15(8):1153-60 [11480555.001]
  • [Cites] Virus Res. 2001 Oct 30;78(1-2):35-43 [11520578.001]
  • [Cites] J Virol. 2002 Feb;76(3):1400-14 [11773414.001]
  • [Cites] Lancet Oncol. 2001 Jan;2(1):18-26 [11905614.001]
  • [Cites] Cancer. 2002 Apr 25;96(2):110-6 [11954028.001]
  • [Cites] J Virol. 2002 Aug;76(15):7843-54 [12097596.001]
  • [Cites] Microbiol Mol Biol Rev. 2002 Sep;66(3):396-406, table of contents [12208996.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):34424-33 [12093802.001]
  • [Cites] Leukemia. 2003 Jan;17(1):26-38 [12529656.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):5775-85 [12477721.001]
  • [Cites] Mol Cancer Ther. 2003 Jun;2(6):563-72 [12813136.001]
  • [Cites] J Virol. 2003 Oct;77(20):11027-39 [14512551.001]
  • [Cites] Adv Cancer Res. 2003;89:69-132 [14587871.001]
  • [Cites] Oncogene. 2003 Dec 8;22(56):8999-9006 [14663478.001]
  • [Cites] Nat Med. 2004 Feb;10(2):197-201 [14730358.001]
  • [Cites] J Virol. 2004 Apr;78(8):3837-45 [15047799.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6629-34 [15100416.001]
  • [Cites] J Biol Chem. 2004 Jun 18;279(25):26287-99 [15090542.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2556-76 [15358581.001]
  • [Cites] J Virol. 2004 Oct;78(20):11077-83 [15452228.001]
  • [Cites] J Virol. 1992 Mar;66(3):1737-45 [1310774.001]
  • [Cites] J Virol. 1993 Apr;67(4):2360-6 [8445734.001]
  • [Cites] Virology. 1994 Nov 1;204(2):656-64 [7941334.001]
  • [Cites] Immunity. 1995 Apr;2(4):341-51 [7536620.001]
  • [Cites] Virology. 1995 Jun 1;209(2):445-56 [7539968.001]
  • [Cites] J Virol. 1996 Jun;70(6):3599-605 [8648694.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S132-45 [8797716.001]
  • [Cites] Br Med Bull. 1997;53(3):539-53 [9374036.001]
  • (PMID = 16014908.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA092009-02; United States / NCRR NIH HHS / RR / RR014324-05; United States / NCI NIH HHS / CA / P01 CA100730-069003; United States / FIC NIH HHS / TW / R03 TW005705; United States / NCI NIH HHS / CA / CA092009-02; United States / NCRR NIH HHS / RR / R01 RR14324; United States / NCI NIH HHS / CA / P01 CA100730-03; United States / FIC NIH HHS / TW / TW05705; United States / NCRR NIH HHS / RR / R01 RR014324; United States / NCI NIH HHS / CA / CA100730-03; United States / NCRR NIH HHS / RR / R01 RR014324-05; United States / NCI NIH HHS / CA / CA100730-069003; United States / NCI NIH HHS / CA / P01 CA100730
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Retroviridae Proteins; 0 / rof protein, Human T-lymphotropic virus 1; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC1181595
  •  go-up   go-down


71. Inagaki A, Ishida T, Ishii T, Komatsu H, Iida S, Ding J, Yonekura K, Takeuchi S, Takatsuka Y, Utsunomiya A, Ueda R: Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors. Int J Cancer; 2006 Jun 15;118(12):3054-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors.
  • Patients with adult T-cell leukemia/lymphoma (ATLL) are in a severely immunocompromised state.
  • We examined the levels of serum cytokines including T helper type 1- (Th1-) associated cytokines [IFN-gamma, TNF-alpha, and interleukin (IL)-2], Th2-associated cytokines (IL-4, -5 and -6) and regulatory T cell-associated cytokines (IL-10 and TGF-beta1) in 94 ATLL patients, 39 asymptomatic human T-cell lymphotropic virus type-1 (HTLV-1) carriers and 50 healthy adult volunteers, to clarify whether elevated levels of particular cytokines are associated with the prognosis of ATLL patients.
  • The IL-10 level significantly increased with disease progression at each step from asymptomatic HTLV-1 carrier to ATLL of the indolent variant (chronic and smoldering subtypes) to ATLL of the aggressive variant (acute and lymphoma subtypes).
  • [MeSH-major] Biomarkers, Tumor / blood. Interleukin-10 / blood. Interleukin-5 / blood. Leukemia, T-Cell / immunology. Th1 Cells / immunology. Th2 Cells / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Human T-lymphotropic virus 1 / isolation & purification. Humans. Interferon-gamma / blood. Interleukin-2 / blood. Interleukin-4 / blood. Interleukin-6 / blood. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prognosis. Transforming Growth Factor beta / blood. Tumor Necrosis Factor-alpha / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16425276.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-2; 0 / Interleukin-5; 0 / Interleukin-6; 0 / Transforming Growth Factor beta; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


72. Takizawa J, Aoki S, Kurasaki T, Higashimura M, Honma K, Kitajima T, Momoi A, Takahashi H, Nakamura N, Furukawa T, Aizawa Y: Successful treatment of adult T-cell leukemia with unrelated cord blood transplantation. Am J Hematol; 2007 Dec;82(12):1113-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of adult T-cell leukemia with unrelated cord blood transplantation.
  • This study reports the first well-documented case of adult T-cell leukemia (ATL) successfully treated with unrelated cord blood transplantation (UCBT).
  • A 49-year-old woman was diagnosed with acute-type of ATL.
  • Chemotherapy induced complete remission, but the human T-cell leukemia virus type 1 (HTLV-1) proviral load was detected in mononuclear cells of her peripheral blood.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / methods. Leukemia-Lymphoma, Adult T-Cell / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696205.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


73. Tabata R, Tabata C, Namiuchi S, Terada M, Yasumizu R, Okamoto T, Nagai T: Adult T-cell lymphoma mimicking Henoch-Schönlein purpura. Mod Rheumatol; 2007;17(1):57-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell lymphoma mimicking Henoch-Schönlein purpura.
  • We report a male patient with adult T-cell lymphoma, who was initially diagnosed clinically as having Henoch-Schönlein purpura (HSP) with abdominal pain and specific purpura.
  • Adult T-cell lymphoma-like cells were minimal and abdominal lymph nodes were transiently swollen, and the symptoms were improved by supportive management.
  • This rare case suggests the importance of skin biopsies to seek the underlying pathology in adult HSP.

  • Genetic Alliance. consumer health - Henoch-Schonlein purpura.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17278024.001).
  • [ISSN] 1439-7595
  • [Journal-full-title] Modern rheumatology
  • [ISO-abbreviation] Mod Rheumatol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, Gockerman JP, Mitchell BS, Appelbaum FR, Larson RA: Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood; 2007 Jun 15;109(12):5136-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.
  • We treated 26 patients with T-cell acute lymphoblastic leukemia (T-ALL) and 13 with T-cell lymphoblastic lymphoma (T-LBL) with nelarabine.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1984 Sep;74(3):951-5 [6332120.001]
  • [Cites] Blood. 1983 Apr;61(4):660-6 [6600944.001]
  • [Cites] Cancer Res. 1985 Aug;45(8):3646-50 [2410098.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6498-502 [2819707.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):813-9 [2185339.001]
  • [Cites] Transplantation. 1991 Oct;52(4):634-40 [1926342.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3352-6 [7614470.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1):70-82 [9045306.001]
  • [Cites] Br J Haematol. 1997 Jun;97(4):896-903 [9217194.001]
  • [Cites] Adv Exp Med Biol. 1984;165 Pt B:309-14 [6609537.001]
  • [Cites] Br J Haematol. 1997 Dec;99(3):671-7 [9401083.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3607-15 [9817282.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1216-30 [10506707.001]
  • [Cites] Biochemistry. 1964 Jan;3:15-8 [14114497.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3376-82 [15908649.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3396-403 [15908652.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):995-1003 [10694549.001]
  • [Cites] Br J Haematol. 2002 Sep;118(3):741-7 [12181040.001]
  • [Cites] Biochemistry. 1981 Jun 9;20(12):3615-21 [6789872.001]
  • [Cites] Cancer Res. 1985 Mar;45(3):1008-14 [3971358.001]
  • (PMID = 17344466.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA047577; United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / N01 CA013612; United States / NCI NIH HHS / CA / U10 CA013612; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / U10 CA041287; United States / NCI NIH HHS / CA / U10 CA047559; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / CA31946
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arabinonucleosides; 60158CV180 / nelarabine
  • [Other-IDs] NLM/ PMC1941786
  •  go-up   go-down


75. Ness KK, Baker KS, Dengel DR, Youngren N, Sibley S, Mertens AC, Gurney JG: Body composition, muscle strength deficits and mobility limitations in adult survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer; 2007 Dec;49(7):975-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body composition, muscle strength deficits and mobility limitations in adult survivors of childhood acute lymphoblastic leukemia.
  • We compared body composition, muscle strength, and mobility between 75 adult survivors of childhood acute lymphoblastic leukemia (ALL) and expected values based on population normative data.
  • CONCLUSIONS: Young adult survivors of childhood ALL have strength and mobility deficits.
  • [MeSH-major] Body Composition. Mobility Limitation. Muscle Weakness. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Survivors
  • [MeSH-minor] Adult. Age Distribution. Cranial Irradiation. Exercise Test. Female. Follow-Up Studies. Growth Hormone / deficiency. Humans. Male. Middle Aged. Sex Distribution. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 17091482.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA106778; United States / NCI NIH HHS / CA / CA55727; United States / NCI NIH HHS / CA / CA85503; United States / NCRR NIH HHS / RR / M01-RR00400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-72-6 / Growth Hormone
  •  go-up   go-down


76. Okumura H, Yamaguchi M, Kotani T, Sugimori N, Sugimori C, Ozaki J, Kondo Y, Yamazaki H, Chuhjo T, Takami A, Ueda M, Ohtake S, Nakao S: Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings. Eur J Haematol; 2007 Feb;78(2):157-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings.
  • Human leukocyte antigen (HLA)-mismatched stem cell transplantation from non-inherited maternal antigen (NIMA)-complementary donors is known to produce stable engraftment without inducing severe graft-versus-host disease (GVHD).
  • We treated two patients with acute myeloid leukemia (AML) and one patient with severe aplastic anemia (SAA) with HLA-mismatched stem cell transplantation (SCT) from NIMA-complementary donors (NIMA-mismatched SCT).
  • Grade III and grade IV acute GVHD developed in patients with AML on day 8 and day 11 respectively, and became a direct cause of death in one patient.
  • The findings suggest that intensive conditioning and immunosuppression after stem cell transplantation are needed in NIMA-mismatched SCT even if donor and recipient microchimerisms is detectable in the donor and recipient before SCT.
  • [MeSH-major] Anemia, Aplastic / surgery. Blast Crisis / surgery. Chimera / immunology. Graft Rejection / immunology. Graft vs Host Disease / immunology. HLA Antigens / genetics. Immunity, Maternally-Acquired. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Peripheral Blood Stem Cell Transplantation / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Tissue Donors. Transplantation Conditioning / methods
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Cord Blood Stem Cell Transplantation. Disease Progression. Fatal Outcome. Female. Histocompatibility. Humans. Isoantigens / immunology. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / pathology. Male. Remission Induction. Siblings. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives


77. Gong SL, Qiu HY, Li JY, Han FL, Song XM, Huang ZX, Wang JM: [Clinical and laboratory characteristics of two acute lymphoblastic leukemia patients with dicentric (9; 20) (p11 - 13; q11)]. Zhonghua Xue Ye Xue Za Zhi; 2006 May;27(5):306-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and laboratory characteristics of two acute lymphoblastic leukemia patients with dicentric (9; 20) (p11 - 13; q11)].
  • OBJECTIVE: To explore the morphologic, immunophenotypic, cytogenetic and clinical features of acute lymphoblastic leukemia (ALL) patients with dicentric (9;.
  • RESULTS: The two ALL patients were positive for CD10 and HLA-DR, showing of B cell origin.
  • [MeSH-major] Chromosomes, Human, Pair 20 / genetics. Chromosomes, Human, Pair 9 / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Base Sequence. Chromosome Banding. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Molecular Sequence Data. Sequence Analysis, DNA

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875578.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


78. Park JS, Yi JW, Jeong SH, Lee HW, Kang SY, Choi JH, Kim HC, Park JE, Kim E, Lim YA, Kim HJ, Cho SR: Comparison of multiplex reverse transcription polymerase chain reaction and conventional cytogenetics as a diagnostic strategy for acute leukemia. Int J Lab Hematol; 2008 Dec;30(6):513-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of multiplex reverse transcription polymerase chain reaction and conventional cytogenetics as a diagnostic strategy for acute leukemia.
  • To clarify the usefulness of multiplex reverse transcription polymerase chain reaction (mRT-PCR) in diagnosing acute leukemia, mRT-PCR detecting 28 different translocations was performed on bone marrow aspirates of 156 patients with acute leukemia, and the results were compared with conventional chromosomal karyotypes.
  • About 113 of 156 patients had acute myeloid leukemia (AML), and 36 had acute lymphoid leukemia (ALL) with patients' ages ranging from 1 to 84 (median: 34.5).
  • In conclusion, although it cannot be a substitute of the conventional chromosome analysis, mRT-PCR could be a complementary diagnostic strategy of acute leukemia.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Humans. Infant. Karyotyping. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983303.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


79. Verheyden S, Ferrone S, Mulder A, Claas FH, Schots R, De Moerloose B, Benoit Y, Demanet C: Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells. Cancer Immunol Immunother; 2009 Jun;58(6):855-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transplantation of acute myeloid leukemia (AML) patients with grafts from related haploidentical donors has been shown to result in a potent graft-versus-leukemia effect.
  • This effect is mediated by NK cells because of the lack of activation of inhibitory killer cell immunoglobulin-like receptors (KIRs) which recognize HLA-Bw4 and HLA-C alleles.
  • Therefore in the present study, utilizing a large panel of human monoclonal antibodies we have measured the level of expression of HLA-A, -B and -C alleles on 20 B-chronic lymphoid leukemic (B-CLL) cell preparations, on 16 B-acute lymphoid leukemic (B-ALL) cell preparations and on 19 AML cell preparations.
  • The potential functional relevance of these abnormalities is suggested by the dose-dependent enhancement of NK cell activation caused by coating the HLA-HLA-Bw4 epitope with monoclonal antibodies on leukemic cells which express NK cell activating ligands.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Apr 15;103(8):3122-30 [15070694.001]
  • [Cites] Leukemia. 2008 Feb;22(2):249-57 [18046448.001]
  • [Cites] Immunol Today. 1990 Jul;11(7):237-44 [2201309.001]
  • [Cites] Science. 1993 May 21;260(5111):1121-4 [8493555.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3349-54 [7686817.001]
  • [Cites] J Exp Med. 1993 Aug 1;178(2):597-604 [8340759.001]
  • [Cites] J Immunol Methods. 1993 Nov 5;166(1):45-54 [8228287.001]
  • [Cites] J Exp Med. 1995 Mar 1;181(3):1133-44 [7532677.001]
  • [Cites] J Exp Med. 1995 Aug 1;182(2):605-9 [7629517.001]
  • [Cites] Hum Immunol. 1997 Aug-Sep;56(1-2):106-13 [9455499.001]
  • [Cites] Hum Immunol. 1998 Aug;59(8):524-8 [9712358.001]
  • [Cites] Tissue Antigens. 1998 Oct;52(4):393-6 [9820605.001]
  • [Cites] Eur J Cancer. 1998 Sep;34(10):1618-22 [9893639.001]
  • [Cites] Blood. 1999 Jul 1;94(1):333-9 [10381530.001]
  • [Cites] J Exp Med. 1999 Jul 19;190(2):205-15 [10432284.001]
  • [Cites] Blood. 2005 Mar 1;105(5):2066-73 [15536144.001]
  • [Cites] Leukemia. 2001 Jan;15(1):128-33 [11243380.001]
  • [Cites] Hum Immunol. 2002 Mar;63(3):200-10 [11872238.001]
  • [Cites] Science. 2002 Mar 15;295(5562):2097-100 [11896281.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3825-7 [12393440.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6178-86 [12414645.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):1000-8 [12648070.001]
  • [Cites] Leuk Res. 2003 Jul;27(7):643-8 [12681364.001]
  • [Cites] Hum Immunol. 2003 Oct;64(10):941-50 [14522091.001]
  • [Cites] Tissue Antigens. 2004 Mar;63(3):204-11 [14989709.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2860-1; author reply 2862 [15033884.001]
  • [Cites] Exp Hematol. 2005 Mar;33(3):344-52 [15730858.001]
  • [Cites] Curr Opin Immunol. 2005 Oct;17(5):553-9 [16085405.001]
  • [Cites] J Immunol. 2006 Nov 15;177(10):6904-10 [17082605.001]
  • [Cites] Cancer Sci. 2007 Jan;98(1):102-8 [17083564.001]
  • [Cites] Blood. 2007 Jul 1;110(1):433-40 [17371948.001]
  • [Cites] Transplantation. 2004 Oct 15;78(7):1081-5 [15480179.001]
  • (PMID = 18841361.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA138188; United States / NCI NIH HHS / CA / R01CA110249; United States / NCI NIH HHS / CA / R01 CA110249; United States / NCI NIH HHS / CA / P01 CA109688; United States / NCI NIH HHS / CA / R01CA113861; United States / NCI NIH HHS / CA / R01 CA113861
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / HLA-A Antigens; 0 / HLA-B Antigens; 0 / HLA-Bw4 antigen; 0 / HLA-C Antigens; 0 / Ligands; 0 / Receptors, KIR
  • [Other-IDs] NLM/ NIHMS395042; NLM/ PMC3426282
  •  go-up   go-down


80. Durkin SS, Guo X, Fryrear KA, Mihaylova VT, Gupta SK, Belgnaoui SM, Haoudi A, Kupfer GM, Semmes OJ: HTLV-1 Tax oncoprotein subverts the cellular DNA damage response via binding to DNA-dependent protein kinase. J Biol Chem; 2008 Dec 26;283(52):36311-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-cell leukemia virus type-1 is the causative agent for adult T-cell leukemia.
  • Previous research has established that the viral oncoprotein Tax mediates the transformation process by impairing cell cycle control and cellular response to DNA damage.

  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2003 Aug;23(16):5836-48 [12897153.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37736-44 [12842897.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):6008-15 [14522929.001]
  • [Cites] Carcinogenesis. 2003 Oct;24(10):1571-80 [12919958.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1496-501 [14571772.001]
  • [Cites] Am J Pathol. 1985 Sep;120(3):464-77 [2412448.001]
  • [Cites] Lancet. 1986 May 3;1(8488):1031-2 [2871307.001]
  • [Cites] Science. 1990 Mar 2;247(4946):1082-4 [2309119.001]
  • [Cites] Blood. 1992 Aug 15;80(4):1012-6 [1498321.001]
  • [Cites] Mol Cell Biol. 1992 Nov;12(11):5041-9 [1406679.001]
  • [Cites] Virology. 1993 Mar;193(1):456-9 [8438579.001]
  • [Cites] J Biol Chem. 1996 Apr 12;271(15):8936-41 [8621537.001]
  • [Cites] J Virol. 1996 Sep;70(9):6347-57 [8709263.001]
  • [Cites] EMBO J. 1997 Aug 15;16(16):5098-112 [9305651.001]
  • [Cites] Mol Cell Biol. 2007 May;27(10):3881-90 [17353268.001]
  • [Cites] Mol Cancer Res. 2007 Jul;5(7):713-24 [17634426.001]
  • [Cites] J Biol Chem. 2007 Oct 5;282(40):29431-40 [17698850.001]
  • [Cites] Nucleic Acids Res. 2003 Dec 1;31(23):6819-27 [14627815.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1247-52 [14734805.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2390-6 [15059890.001]
  • [Cites] Immunol Rev. 2004 Aug;200:132-41 [15242401.001]
  • [Cites] Int J Oncol. 2004 Aug;25(2):461-8 [15254745.001]
  • [Cites] DNA Repair (Amst). 2004 Aug-Sep;3(8-9):909-18 [15279776.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2495-9 [15353302.001]
  • [Cites] J Biol Chem. 2004 Sep 17;279(38):39408-13 [15258142.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] Lancet. 1985 Aug 24;2(8452):407-10 [2863442.001]
  • [Cites] Mol Cell Biol. 2000 May;20(10):3377-86 [10779327.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32906-10 [10969065.001]
  • [Cites] J Virol. 2001 Jan;75(1):396-407 [11119608.001]
  • [Cites] Nat Genet. 2001 Mar;27(3):247-54 [11242102.001]
  • [Cites] Curr Opin Cell Biol. 2001 Apr;13(2):225-31 [11248557.001]
  • [Cites] Mol Cell Biol. 2001 Jun;21(11):3642-51 [11340158.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3612-20 [11369658.001]
  • [Cites] Curr Biol. 2001 Nov 13;11(22):R920-4 [11719239.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15084-8 [11742099.001]
  • [Cites] J Hum Genet. 2001;46(12):706-11 [11776383.001]
  • [Cites] Science. 2002 Jul 26;297(5581):547-51 [12142523.001]
  • [Cites] Genes Dev. 2002 Sep 15;16(18):2333-8 [12231622.001]
  • [Cites] Biochemistry. 2002 Oct 22;41(42):12706-14 [12379113.001]
  • [Cites] EMBO J. 2002 Nov 15;21(22):6275-87 [12426399.001]
  • [Cites] Leukemia. 2003 Jan;17(1):26-38 [12529656.001]
  • [Cites] Virology. 2003 Jan 20;305(2):229-39 [12573569.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):155-68 [12612651.001]
  • [Cites] J Biol Chem. 1997 Sep 26;272(39):24097-100 [9305850.001]
  • [Cites] Nat Genet. 1997 Dec;17(4):483-6 [9398856.001]
  • [Cites] J Virol. 1998 Aug;72(8):6348-55 [9658074.001]
  • [Cites] Mol Cell. 1998 Jul;2(1):1-8 [9702186.001]
  • [Cites] Virology. 1999 Jan 20;253(2):155-61 [9918874.001]
  • [Cites] Exp Cell Res. 1999 Mar 15;247(2):525-33 [10066380.001]
  • [Cites] J Virol. 1999 May;73(5):4299-304 [10196328.001]
  • [Cites] Genes Dev. 1999 Apr 15;13(8):916-34 [10215620.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 2;91(11):933-42 [10359545.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Dec;311(3):1062-70 [15273254.001]
  • [Cites] Am J Hematol. 2005 Feb;78(2):100-7 [15682421.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):949-61 [15592499.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):12041-50 [15668230.001]
  • [Cites] J Biol Chem. 2005 Apr 15;280(15):14709-15 [15677476.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):864-70 [15829956.001]
  • [Cites] Retrovirology. 2005;2:16 [15743528.001]
  • [Cites] Retrovirology. 2005;2:45 [16014171.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5986-95 [16155605.001]
  • [Cites] Cancer Lett. 2005 Nov 18;229(2):171-9 [16129552.001]
  • [Cites] Mol Cell Biol. 2005 Dec;25(24):10842-52 [16314509.001]
  • [Cites] Oncogene. 2006 Jan 19;25(3):438-47 [16158050.001]
  • [Cites] J Clin Invest. 2006 Apr;116(4):974-83 [16585963.001]
  • [Cites] J Cell Biol. 2006 Apr 24;173(2):195-206 [16618811.001]
  • [Cites] Nucleic Acids Res. 2006;34(8):2408-17 [16682448.001]
  • [Cites] DNA Repair (Amst). 2006 Sep 8;5(9-10):1042-8 [16822724.001]
  • [Cites] J Biol Chem. 2006 Oct 20;281(42):31705-12 [16923801.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18137-42 [17110439.001]
  • [Cites] J Biol Chem. 2007 Apr 20;282(16):11950-9 [17272270.001]
  • [Cites] J Cell Biol. 2007 Apr 23;177(2):219-29 [17438073.001]
  • [Cites] Oncogene. 2003 Jun 12;22(24):3734-41 [12802280.001]
  • [Cites] Immunol Rev. 2003 Aug;194:77-95 [12846809.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(15):5269-81 [12861013.001]
  • (PMID = 18957425.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA076595; United States / NCI NIH HHS / CA / CA-76595
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / DNA-Binding Proteins; 0 / Gene Products, tax; 0 / Ku autoantigen; EC 2.7.1.11 / Checkpoint Kinase 2; EC 2.7.11.1 / CHEK2 protein, human; EC 2.7.11.1 / DNA-Activated Protein Kinase; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC2605996
  •  go-up   go-down


81. Pichler K, Kattan T, Gentzsch J, Kress AK, Taylor GP, Bangham CR, Grassmann R: Strong induction of 4-1BB, a growth and survival promoting costimulatory receptor, in HTLV-1-infected cultured and patients' T cells by the viral Tax oncoprotein. Blood; 2008 May 1;111(9):4741-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-cell leukemia virus type 1 (HTLV-1), the cause of adult T-cell leukemia, stimulates the growth of infected T cells in cultures and in nonleukemic patients.
  • In the latter, HTLV-1 is found in long-term persisting T-cell clones.
  • Up-regulated 4-1BB expression was a consistent feature of all HTLV-1-infected cell lines, whether patient-derived or in vitro transformed.
  • The ligand of 4-1BB was also found on transformed T-cell lines, opening up the possibility of autostimulation.
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation. Clone Cells / virology. Human T-lymphotropic virus 1. Humans. NF-kappa B. Up-Regulation

  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18276843.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD137; 0 / Gene Products, tax; 0 / NF-kappa B; 0 / TNFRSF9 protein, human
  •  go-up   go-down


82. Semmes OJ, Cazares LH, Ward MD, Qi L, Moody M, Maloney E, Morris J, Trosset MW, Hisada M, Gygi S, Jacobson S: Discrete serum protein signatures discriminate between human retrovirus-associated hematologic and neurologic disease. Leukemia; 2005 Jul;19(7):1229-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The human T-cell leukemia virus type I (HTLV-I) is the causative agent for adult T-cell leukemia (ATL) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
  • [MeSH-major] Blood Proteins / analysis. Leukemia-Lymphoma, Adult T-Cell / blood. Paraparesis, Tropical Spastic / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Regression Analysis. Reproducibility of Results. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15889159.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Proteins
  •  go-up   go-down


83. Asnafi V, Le Noir S, Lhermitte L, Gardin C, Legrand F, Vallantin X, Malfuson JV, Ifrah N, Dombret H, Macintyre E: JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study. Br J Haematol; 2010 Jan;148(1):178-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study.
  • [MeSH-major] Janus Kinase 1 / genetics. Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Humans

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764985.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / Janus Kinase 1
  •  go-up   go-down


84. Kletting P, Kull T, Reske SN, Glatting G: Comparing time activity curves using the Akaike information criterion. Phys Med Biol; 2009 Nov 7;54(21):N501-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Aged. Antigens, CD / chemistry. Cell Adhesion Molecules / chemistry. Female. Humans. Indium Radioisotopes / pharmacokinetics. Kinetics. Leukemia, Myeloid, Acute / radiotherapy. Male. Middle Aged. Models, Statistical. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Radiopharmaceuticals / pharmacokinetics. Yttrium Radioisotopes / pharmacokinetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820266.001).
  • [ISSN] 1361-6560
  • [Journal-full-title] Physics in medicine and biology
  • [ISO-abbreviation] Phys Med Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD66 antigens; 0 / Cell Adhesion Molecules; 0 / Indium Radioisotopes; 0 / Radiopharmaceuticals; 0 / Yttrium Radioisotopes
  •  go-up   go-down


85. Khadilkar UN, Mathai AM, Chakrapani M, Prasad K: Rare association of papillary carcinoma of thyroid with adult T-cell lymphoma/leukemia. Indian J Pathol Microbiol; 2010 Jan-Mar;53(1):125-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare association of papillary carcinoma of thyroid with adult T-cell lymphoma/leukemia.
  • We report a rare association of papillary carcinoma of thyroid in an elderly lady with adult T-cell lymphoma/leukemia.
  • Fine needle aspiration of the thyroid, neck nodes and evaluation of the bone marrow and peripheral blood helped in the diagnosis of papillary cancer coexisting with adult T-cell lymphoma/leukemia.
  • [MeSH-major] Carcinoma, Papillary / complications. Leukemia-Lymphoma, Adult T-Cell / complications. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Thyroid Gland / pathology. Thyroid Neoplasms / complications
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Bone Marrow / pathology. Female. Histocytochemistry. Humans. Immunohistochemistry. Leukemia. Middle Aged. Neck / radiography. Thyroid Nodule. Tomography

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20090241.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


86. De Braekeleer E, Meyer C, Douet-Guilbert N, Morel F, Le Bris MJ, Berthou C, Arnaud B, Marschalek R, Férec C, De Braekeleer M: Complex and cryptic chromosomal rearrangements involving the MLL gene in acute leukemia: a study of 7 patients and review of the literature. Blood Cells Mol Dis; 2010 Apr 15;44(4):268-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complex and cryptic chromosomal rearrangements involving the MLL gene in acute leukemia: a study of 7 patients and review of the literature.
  • We recommend a systematic approach to be used in all cases of acute leukemia starting with FISH analyses using a commercially available MLL split signal probe.
  • [MeSH-major] Chromosome Aberrations. Leukemia / genetics. Myeloid-Lymphoid Leukemia Protein / genetics
  • [MeSH-minor] Acute Disease. Adenocarcinoma. Adult. Aged. Blast Crisis / genetics. Child, Preschool. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 11 / ultrastructure. Duodenal Neoplasms. Female. Histone-Lysine N-Methyltransferase. Humans. In Situ Hybridization, Fluorescence. Infant. Infant, Newborn. Leukemia, Monocytic, Acute / congenital. Leukemia, Monocytic, Acute / genetics. Leukemia, Myelomonocytic, Acute / genetics. Leukemia, Myelomonocytic, Chronic / pathology. Male. Mutagenesis, Insertional. Neoplasms, Second Primary / genetics. Oncogene Proteins, Fusion / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Prostatic Neoplasms. Sequence Deletion. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20206559.001).
  • [ISSN] 1096-0961
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Number-of-references] 70
  •  go-up   go-down


87. Liu XP, Zhu XF, Wang JX, Mi YC, Zou Y, Chen YM, Li CW, Dai Y, Qin S, Xiao JG, Xu FY, Gong JY, Wang SP, Yu CL, Fan J: [A comparative cytogenetic analysis in large scale between adult and childhood patients with acute lymphoblastic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec;17(6):1399-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A comparative cytogenetic analysis in large scale between adult and childhood patients with acute lymphoblastic leukemia].
  • This study was purposed to comparatively analyze the cytogenetic characteristics between 566 cases of adult acute lymphoblastic leukemia (aALL) and 586 cases of childhood acute lymphoblastic leukemia (cALL).

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20030914.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


88. Poitras JL, Dal Cin P, Aster JC, Deangelo DJ, Morton CC: Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia. Genes Chromosomes Cancer; 2008 Oct;47(10):884-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia.
  • In addition, less common aberrations (particularly gene fusions) involving JAK2 have been described in acute leukemias.
  • In this report, we identify SSBP2 as a new JAK2 fusion partner in a patient with pre-B cell acute lymphocytic leukemia.
  • [MeSH-major] Chromosomes, Human, Pair 5 / genetics. Chromosomes, Human, Pair 9 / genetics. DNA-Binding Proteins / genetics. Janus Kinase 2 / genetics. Oncogene Proteins, Fusion / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Acute Disease. Adult. Humans. In Situ Hybridization, Fluorescence. Male. Mutation. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18618714.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01CA066996-11A1
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / SSBP2 protein, human; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


89. Malan R, Berini CA, Eirin ME, Delfino CM, Pedrozo W, Krupp R, García Plichta A, Biglione MM: [Seroprevalence of HTLV-1/2 in blood donors from Misiones Province]. Medicina (B Aires); 2010;70(1):71-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-cell Lymphotropic viruses type 1 (HTLV-1), the first human oncoretrovirus to be discovered, is the etiologic agent of Adult T-cell Leukemia (ATL) and HTLV-1 Associated Mielopathy or Tropical Spastic Paraparesis (HAM/TSP).
  • [MeSH-minor] Adult. Argentina / epidemiology. Enzyme-Linked Immunosorbent Assay. Female. Human T-lymphotropic virus 1 / isolation & purification. Human T-lymphotropic virus 2 / isolation & purification. Humans. Male. Seroepidemiologic Studies

  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20228028.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


90. Yamamoto K, Nagata K, Morita Y, Inagaki K, Hamaguchi H: Isodicentric Philadelphia chromosome in acute lymphoblastic leukemia with der(7;12)(q10;q10). Leuk Res; 2007 May;31(5):713-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isodicentric Philadelphia chromosome in acute lymphoblastic leukemia with der(7;12)(q10;q10).
  • We describe here the first case of acute lymphoblastic leukemia (ALL) with an isodicentric Philadelphia [idic(Ph)] chromosome.
  • The idic(Ph) chromosome was spindle-shaped and supposed to be formed by two Ph chromosomes joined at their q terminals, whereas idic(Ph) chromosomes in chronic myelogenous leukemia (CML) have been shown to be fused at the satellite regions of p arms.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 12. Chromosomes, Human, Pair 7. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Adult. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16979235.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


91. Primo J, Siqueira I, Nascimento MC, Oliveira MF, Farre L, Carvalho EM, Bittencourt AL: High HTLV-1 proviral load, a marker for HTLV-1 associated myelopathy/tropical spastic paraparesis, is also detected in patients with infective dermatitis associated with HTLV-1. Braz J Med Biol Res; 2009 Aug;42(8):761-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Salvador (BA, Brazil) is an endemic area for human T-cell lymphotrophic virus type 1 (HTLV-1).
  • HTLV-1 carriers may develop a variety of diseases such as adult T-cell leukemia/lymphoma, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and infective dermatitis associated with HTLV-1 (IDH).
  • The replication of HTLV-1 has been reported to be greater in adult HAM/TSP patients than in asymptomatic HTLV-1 carriers.
  • In the current study, the proviral load of 28 children and adolescents with IDH not associated with HAM/TSP was determined and the results were compared to those obtained in 28 HTLV-1 adult carriers and 28 adult patients with HAM/TSP.

  • Genetic Alliance. consumer health - Spastic paraparesis.
  • Genetic Alliance. consumer health - Tropical spastic paraparesis.
  • Genetic Alliance. consumer health - HTLV-1 associated myelopathy/tropical spastic paraparesis.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 1998 Apr;134(4):439-44 [9554295.001]
  • [Cites] J Neurovirol. 1998 Dec;4(6):586-93 [10065900.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1999 Apr 29;354(1384):691-700 [10365395.001]
  • [Cites] Clin Infect Dis. 2005 Jun 1;40(11):e90-6 [15889351.001]
  • [Cites] Clin Infect Dis. 2005 Aug 15;41(4):535-41 [16028164.001]
  • [Cites] J Infect Dis. 2006 Sep 1;194(5):552-60 [16897651.001]
  • [Cites] Lancet. 1991 Dec 21-28;338(8782-8783):1593-4 [1683991.001]
  • [Cites] Pediatr Infect Dis J. 2000 Jun;19(6):560-5 [10877174.001]
  • [Cites] Oncogene. 2000 Oct 12;19(43):4954-60 [11042682.001]
  • [Cites] J Virol Methods. 2002 Apr;102(1-2):37-51 [11879691.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):527-31 [14657765.001]
  • [Cites] J Infect Dis. 2004 Jan 1;189(1):41-5 [14702151.001]
  • [Cites] Clin Infect Dis. 2008 Feb 1;46(3):440-2 [18173359.001]
  • (PMID = 19578703.001).
  • [ISSN] 1414-431X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Grant] United States / FIC NIH HHS / TW / D43 TW007127; United States / FIC NIH HHS / TW / TW007127-05; United States / FIC NIH HHS / TW / D43 TW007127-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DNA, Viral
  • [Other-IDs] NLM/ NIHMS241997; NLM/ PMC2963476
  •  go-up   go-down


92. Chlichlia K, Khazaie K: HTLV-1 Tax: Linking transformation, DNA damage and apoptotic T-cell death. Chem Biol Interact; 2010 Nov 5;188(2):359-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HTLV-1 Tax: Linking transformation, DNA damage and apoptotic T-cell death.
  • The human T-cell leukemia virus type I (HTLV-1) is the causative agent of adult T-cell leukemia (ATL), an aggressive CD4-positive T-cell neoplasia.
  • During the course of HTLV-1 infection, the dysregulation of cell-cycle checkpoints and the suppression of DNA damage repair is tightly linked to the activity of the viral oncoprotein Tax.
  • Tax activity is associated with production of reactive oxygen intermediates (ROS), chromosomal instability and DNA damage, apoptotic cell death and cellular transformation.
  • [MeSH-major] Apoptosis. Cell Transformation, Viral. DNA Damage. Gene Products, tax / metabolism. Human T-lymphotropic virus 1 / genetics. Leukemia-Lymphoma, Adult T-Cell / virology. T-Lymphocytes / cytology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20558150.001).
  • [ISSN] 1872-7786
  • [Journal-full-title] Chemico-biological interactions
  • [ISO-abbreviation] Chem. Biol. Interact.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / tax protein, Human T-lymphotrophic virus 1
  •  go-up   go-down


93. Pise-Masison CA, Brady JN: Setting the stage for transformation: HTLV-1 Tax inhibition of p53 function. Front Biosci; 2005 Jan 1;10:919-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-lymphotropic virus type 1 (HTLV-1) is the causative agent of adult T-cell leukemia and tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM).
  • Tax has been shown to regulate viral and cellular gene expression and to functionally interfere with proteins involved in cell-cycle progression and DNA repair.
  • This review will concentrate on the ability of Tax to promote cellular proliferation through activation of the NF-kappaB pathway while inhibiting the cell-cycle checkpoint and apoptotic function of the tumor suppressor gene p53.
  • [MeSH-major] Cell Transformation, Neoplastic. Gene Products, tax / chemistry. Human T-lymphotropic virus 1 / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Animals. Cell Cycle. Cell Proliferation. DNA Repair. Humans. NF-kappa B / metabolism. Terminal Repeat Sequences

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15569630.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / NF-kappa B; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 155
  •  go-up   go-down


94. Bonnefoix T, Callanan M: Challenging the adult T-cell leukemia/lymphoma (ATL) stem cell concept based on limiting dilution transplantation assay. Blood; 2010 Mar 11;115(10):2117-8; author reply 2118
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenging the adult T-cell leukemia/lymphoma (ATL) stem cell concept based on limiting dilution transplantation assay.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / pathology. Neoplastic Stem Cells / pathology
  • [MeSH-minor] Animals. Antigens, CD / metabolism. Antigens, CD38 / metabolism. Cell Separation / methods. Genes, pX. Humans. Membrane Glycoproteins / metabolism. Mice. Mice, Transgenic. Neoplasm Transplantation / methods. Proto-Oncogene Proteins c-kit / metabolism. Receptors, Transferrin / metabolism. Transplantation, Heterologous. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2009 Sep 24;114(13):2709-20 [19584402.001]
  • (PMID = 20223932.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Evaluation Studies; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD71 antigen; 0 / Membrane Glycoproteins; 0 / Receptors, Transferrin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / Cd38 protein, mouse
  •  go-up   go-down


95. Yano H, Ishida T, Imada K, Sakai T, Ishii T, Inagaki A, Iida S, Uchiyama T, Ueda R: Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia/lymphoma using G-CSF. Br J Haematol; 2008 Mar;140(5):586-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia/lymphoma using G-CSF.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / therapy. Receptors, CCR4 / immunology
  • [MeSH-minor] Adult. Animals. Antineoplastic Agents / therapeutic use. Disease Models, Animal. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Mice. Mice, SCID

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3625-34 [14506150.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2127-33 [15026353.001]
  • [Cites] J Exp Med. 2004 Jun 21;199(12):1659-69 [15210744.001]
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] Leukemia. 2006 Dec;20(12):2162-8 [17039235.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7529-39 [15569983.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6047-57 [16155611.001]
  • [Cites] Nat Rev Immunol. 2006 May;6(5):343-57 [16622479.001]
  • [Cites] Cancer Sci. 2006 Nov;97(11):1139-46 [16952304.001]
  • [Cites] Jpn J Cancer Res. 1996 Sep;87(9):887-92 [8878449.001]
  • (PMID = 18205860.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / CCR4 protein, human; 0 / Receptors, CCR4; 134088-74-7 / nartograstim; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  • [Other-IDs] NLM/ PMC2268953
  •  go-up   go-down


96. Tanaka M, Taguchi J, Hyo R, Kawano T, Hashimoto C, Motomura S, Kodama F, Kobayashi S, Okabe G, Maruta A, Nagao T, Ishigatsubo Y: Human herpesvirus-6 encephalitis after unrelated cord blood transplantation. Leuk Lymphoma; 2005 Apr;46(4):561-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we describe 2 patients with acute leukemia in whom human herpesvirus-6 (HHV-6) encephalitis developed after cord blood transplantation.
  • When neurological symptoms and signs appear in hematopoietic stem cell transplantation recipients, we should consider HHV-6 encephalitis and promptly and empirically treat them with gancyclovir or foscarnet.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / adverse effects. Encephalitis, Viral / diagnosis. Herpesvirus 6, Human. Leukemia, Monocytic, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Roseolovirus Infections / diagnosis
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019484.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


97. Nonaka M, Uota S, Saitoh Y, Takahashi M, Sugimoto H, Amet T, Arai A, Miura O, Yamamoto N, Yamaoka S: Role for protein geranylgeranylation in adult T-cell leukemia cell survival. Exp Cell Res; 2009 Jan 15;315(2):141-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role for protein geranylgeranylation in adult T-cell leukemia cell survival.
  • Adult T-cell leukemia (ATL) is a fatal lymphoproliferative disease that develops in human T-cell leukemia virus type I (HTLV-I)-infected individuals.
  • Here, we report that statins hinder the survival of ATL cells and induce apoptotic cell death.
  • Inhibition of protein geranylgeranylation is responsible for these effects, since simultaneous treatment with isoprenoid precursors, geranylgeranyl pyrophosphate or farnesyl pyrophosphate, but not a cholesterol precursor squalene, restored the viability of ATL cells.
  • Simvastatin inhibited geranylgeranylation of small GTPases Rab5B and Rac1 in ATL cells, and a geranylgeranyl transferase inhibitor GGTI-298 reduced ATL cell viability more efficiently than a farnesyl transferase inhibitor FTI-277.
  • These results not only unveil an important role for protein geranylgeranylation in ATL cell survival, but also implicate therapeutic potentials of statins in the treatment of ATL.
  • [MeSH-minor] Adult. Benzamides / pharmacology. Caspase 3 / metabolism. Cell Line, Tumor. Cell Nucleus / drug effects. Cell Nucleus / metabolism. Cell Survival / drug effects. Cell Survival / physiology. Enzyme Inhibitors / pharmacology. Humans. Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology. I-kappa B Proteins / metabolism. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / pathology. Methionine / analogs & derivatives. Methionine / pharmacology. NF-kappa B / metabolism. Phosphorylation / drug effects. Polyisoprenyl Phosphates / pharmacology. Sesquiterpenes / pharmacology. rab5 GTP-Binding Proteins / metabolism. rac1 GTP-Binding Protein / metabolism

  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18992741.001).
  • [ISSN] 1090-2422
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Enzyme Inhibitors; 0 / FTI 277; 0 / GGTI 298; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / I-kappa B Proteins; 0 / NF-kappa B; 0 / Polyisoprenyl Phosphates; 0 / RAC1 protein, human; 0 / Sesquiterpenes; 139874-52-5 / NF-kappaB inhibitor alpha; 6699-20-3 / geranylgeranyl pyrophosphate; 79W6B01D07 / farnesyl pyrophosphate; AE28F7PNPL / Methionine; EC 3.4.22.- / Caspase 3; EC 3.6.5.2 / rab5 GTP-Binding Proteins; EC 3.6.5.2 / rac1 GTP-Binding Protein
  •  go-up   go-down


98. Gunduz C, Biray C, Kosova B, Yilmaz B, Eroglu Z, Sahin F, Omay SB, Cogulu O: Evaluation of Manisa propolis effect on leukemia cell line by telomerase activity. Leuk Res; 2005 Nov;29(11):1343-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of Manisa propolis effect on leukemia cell line by telomerase activity.
  • Propolis is shown to inhibit cell division and protein synthesis.
  • In this study we aimed to evaluate hTERT ratios in propolis-treated T-cell acute lymphoblastic leukemia (CCFR-CEM) cell line.
  • Cell counts and cell viability of propolis-treated and propolis-free T-cell acute lymphoblastic leukemia (CCFR-CEM) cell line were assessed by trypan blue dye exclusion test and MTT assay.
  • The LightCycler instrument was used (online real-time PCR) for the quantification of hTERT in CCFR-CEM cell line.
  • It had almost no cytotoxic effect and caused 30, 30, 22 and 12% decrease in cell counts after 24, 48, 72 and 96 h respectively which is statistically significant.
  • [MeSH-major] DNA-Binding Proteins / metabolism. Leukemia-Lymphoma, Adult T-Cell / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Propolis / pharmacology. Telomerase / metabolism
  • [MeSH-minor] Cell Count. Cell Culture Techniques / methods. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Humans. Sensitivity and Specificity. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16055186.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 9009-62-5 / Propolis; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


99. Lv L, Wu C, Sun H, Zhu S, Yang Y, Chen X, Fu H, Bao L: Combined 677CC/1298AC genotypes of methylenetetrahydrofolate reductase (MTHFR ) reduce susceptibility to precursor B lymphoblastic leukemia in a Chinese population. Eur J Haematol; 2010 Jun;84(6):506-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined 677CC/1298AC genotypes of methylenetetrahydrofolate reductase (MTHFR ) reduce susceptibility to precursor B lymphoblastic leukemia in a Chinese population.
  • It has been suggested that two MTHFR polymorphisms, 677C>T and 1298A>C, influence risk of acute lymphoblastic leukemia (ALL).
  • Here, we report a case-control study of 127 Chinese patients with adult precursor B lymphoblastic leukemia (B-ALL) to examine correlation between the MTHFR polymorphisms and B-ALL susceptibility in adults.
  • The prevalence for joint MTHFR genotypes 677CC/1298AC was significantly lower in the female B-ALL cases than in the controls [odds ratio (OR) = 0.06, 95% CI = 0.00-0.53, P = 0.0033] and no differences among the men [OR = 0.71, 95% CI = 0.20-2.53, P = 0.55], suggesting that protective effects of combined MTHFR 677CC/1298AC genotypes on susceptibility of adult B-ALL are gender bias toward women with 677CC/1298AC women being at a 17-fold reduced odds to develop B-ALL.
  • [MeSH-major] Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Single Nucleotide. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Aged. Asian Continental Ancestry Group / genetics. Base Sequence. Case-Control Studies. China. Confidence Intervals. DNA Primers / genetics. Female. Gene Frequency. Genetic Predisposition to Disease. Genotype. Haplotypes. Humans. Male. Middle Aged. Odds Ratio. Sex Characteristics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20374270.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


100. Gallo RC: The discovery of the first human retrovirus: HTLV-1 and HTLV-2. Retrovirology; 2005;2:17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These efforts finally yielded success following the discovery of IL-2 and its use to culture adult T cell lymphoma/leukemia cells.
  • [MeSH-major] Human T-lymphotropic virus 1 / isolation & purification. Human T-lymphotropic virus 2 / isolation & purification. Leukemia, T-Cell / history. Lymphoma, T-Cell / history

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1970 Jun 27;226(5252):1209-11 [4316300.001]
  • [Cites] Virology. 1981 Jul 15;112(1):355-60 [6166122.001]
  • [Cites] J Mol Biol. 1970 Sep 14;52(2):195-219 [5274398.001]
  • [Cites] Nat New Biol. 1972 Feb 9;235(58):170-1 [4501200.001]
  • [Cites] Nature. 1981 Nov 19;294(5838):268-71 [6272125.001]
  • [Cites] Nature. 1981 Nov 19;294(5838):273-5 [6272127.001]
  • [Cites] Cancer Res. 1981 Nov;41(11 Pt 1):4738-9 [6975656.001]
  • [Cites] J Exp Med. 1981 Dec 1;154(6):1957-64 [6274993.001]
  • [Cites] Nat New Biol. 1972 Nov 15;240(98):67-72 [4117890.001]
  • [Cites] Biochem Biophys Res Commun. 1974 Apr 8;57(3):934-48 [4133312.001]
  • [Cites] J Natl Cancer Inst. 1974 Dec;53(6):1583-8 [4436864.001]
  • [Cites] J Biol Chem. 1975 Mar 10;250(5):1702-9 [46229.001]
  • [Cites] Bibl Haematol. 1975;(40):59-66 [51637.001]
  • [Cites] Nature. 1970 Jun 27;226(5252):1211-3 [4316301.001]
  • [Cites] Nature. 1981 Dec 24;294(5843):770-1 [6275274.001]
  • [Cites] J Immunol. 1982 Mar;128(3):1122-7 [6976987.001]
  • [Cites] Lancet. 1982 Mar 20;1(8273):683 [6121990.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] Science. 1982 Nov 5;218(4572):571-3 [6981847.001]
  • [Cites] Nature. 1982 Nov 4;300(5887):63-6 [6982418.001]
  • [Cites] Science. 1982 Feb 19;215(4535):975-8 [6760397.001]
  • [Cites] Science. 1983 Feb 18;219(4586):856-9 [6600519.001]
  • [Cites] EMBO J. 1986 Sep;5(9):2163-70 [3023059.001]
  • [Cites] Retrovirology. 2005;2:16 [15743528.001]
  • [Cites] J Biol Chem. 1967 Nov 10;242(21):5059-68 [6058946.001]
  • [Cites] J Biol Chem. 1968 Oct 10;243(19):4936-42 [5679973.001]
  • [Cites] J Biol Chem. 1968 Oct 10;243(19):4943-51 [5679974.001]
  • [Cites] Science. 1972 May 19;176(4036):798-800 [4113240.001]
  • [Cites] Proc Natl Acad Sci U S A. 1972 Nov;69(11):3228-32 [4117771.001]
  • [Cites] Acta Haematol. 1975;54(4):201-9 [52980.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 Oct;72(10):4137-41 [172897.001]
  • [Cites] Science. 1976 Sep 10;193(4257):1007-8 [181845.001]
  • [Cites] J Immunol. 1977 Jul;119(1):131-8 [141483.001]
  • [Cites] Biochemistry. 1977 Jun 28;16(13):2874-80 [69438.001]
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] Nature. 1977 Nov 24;270(5635):347-9 [271272.001]
  • [Cites] Virology. 1978 Feb;84(2):359-73 [74897.001]
  • [Cites] Int J Cancer. 1979 Nov 15;24(5):616-23 [316807.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Mar;78(3):1887-91 [6262827.001]
  • [Cites] J Virol. 1981 Jun;38(3):906-15 [6264163.001]
  • [CommentIn] Retrovirology. 2005;2:15 [15743525.001]
  • (PMID = 15743526.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC555587
  •  go-up   go-down






Advertisement